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DISSERTATION TITLE: A study on ventilator associated pneumonia  with 
special reference to multidrug resistant pathogens in a tertiary care  hospital. 
ABSTRACT : 
Background: 
Ventilator Associated Pneumonia (VAP) is the most frequent intensive care unit 
(ICU) acquired infection. The aetiology of VAP varies with different patient 
populations and types of ICUs. 
Methodology: 
Endotracheal aspirates/bronchioalveolar lavage were collected from patients on 
mechanical ventilation for > 48hrs and processed quantitatively to determine the 
various aetiological agents causing VAP and the prevalence of multidrug resistant 
(MDR) pathogens.Combination disc method, Modified Hodge test, EDTA Combined 
disc test and AmpC disc test were performed for the detection of extended spectrum 
beta lactamases (ESBL), carbapenemases, metallo betalactamases (MBL)and AmpC β 
lactamases respectively. 
Results: 
The incidence of VAP was 16 per 1000 ventilator days.In this study,34.8% of the 
cases were early onset VAP,while 65.2% were late onset VAP. 
Klebsiella pneumonia,Klebsiella oxytoca and Pseudomonas aeruginosa  were more 
common in early onset VAP, while non fermenters (Acinetobacter baumannii and 
Pseudomonas aeruginosa)were predominantly associated with late onset VAP.70% of 
the isolated VAP pathogens were multidrug resistant. ESBL was produced by 100% 
Escherichia coli, 67% of Klebsiella pneumonia ,100% of Klebsiella oxytoca 
respectively. MBL was produced by 33% of P. aeruginosa and 33% of Acinetobacter 
baumannii.AmpC betalactamases were produced by 17% of Pseudomonas 
aeruginosa,22% of Acinetobacter baumannii  and 33% of Klebsiella pneumonia.Of 
the S. aureus isolates, 100% were methicillin resistant. Prior antibiotic 
therapy,reintubation,Emergency intubation and hospitalization of five days or more 
were common risk factors associated with VAP. 
Conclusions: 
VAP is increasingly associated with MDR pathogens. Production of ESBL, AmpC 
betalactamases and metallo betalactamases were responsible for the multidrug 
resistance of these pathogens. Increasing prevalence of MDR pathogens in patients 
with late onset VAP indicate that appropriate broad spectrum antibiotics should be 
used to treat them.It is useful in implementing simple and effective preventive 
measures including  precaution during emergency intubation, minimizing the 
occurrence of reintubation, and judicious use of antibiotics. 
Key words:Ventilator Associated pneumonia,Intensive care unit,Extended spectrum 
beta lactamase,AmpC beta lactamase,Metallobetalactamase. 
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INTRODUCTION 
Ventilator-associated pneumonia (VAP) is defined as pneumonia that occurs more 
than 48 hrs following endotracheal intubation and initiation of mechanical 
ventilation.It is characterized by the presence of a new or progressive  radiographic 
infiltrate, fever, altered white blood cell count,changes in sputum characteristics and 
detection of a causative pathogen.(1) 
VAP is the frequent ICU acquired infection among patients on Mechanical 
Ventilation.(1)VAP is a subgroup of Hospital Acquired Pneumonia.It occurs in 9-
27% of patients on ventilator.(2)India has an overall crude mortality of 67.4% in 
patients with pneumoniain ICU, with 40% of the mortality is attributable to 
infection alone.(6) 
VAP is usually categorised as early onset and late onset VAP.Early onset VAP 
occurs within first 4 days of mechanical ventilation (MV),usually carries a good 
prognosis and are likely to be due to organisms sensitive to antibiotics. Late 
onsetVAPdevelops  five (or more) days after initiation of  Mechanical ventilation.It 
is caused by MDRpathogens and is associated with increase in patient mortality and 
morbidity (3).  
The risk of VAP is highest early in the course of hospital stay, and is estimated to 
be 3% per day during the first 5days of ventilation, 2% per day during  5 -10 days of 
Mechanical ventilation and 1%per day after 10 days.(2)VAP needs to be diagnosed 
earlyand treated with appropriate antibiotics as reported by differentstudies,which 
showed that delayed administration of antibiotic therapy that is appropriate has been 
associated with increased mortalityin patients with VAP.(2,3) 
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The diagnosis of pneumonia in mechanically ventilated patients is based on the 
combination of clinical, radiological and microbiological criteria.(7)The lower 
respiratorytract samples obtained either by 
bronchoscopic(eg.BAL,PSB)ornonbronchoscopic methods(Endotracheal aspirates) 
are used in the diagnosis of VAP.The endotracheal aspirates are easy to collect and 
have a high sensitivity.(5) 
The common pathogens causing VAP  includePseudomonas aeruginosa, 
Acinetobacterspecies, Klebsiellapneumoniae, Enterobacterspecies, and MRSA 
(methicillin Resistant Staphylococcus aureus).Among them Pseudomonas and 
Acinetobacter species are often multidrug resistant which is attributed to the 
production of ESBL(Extended spectrum beta lactamases),Amp C beta lactamases 
and  metallo beta lactamases.(2) 
Thus ,VAP poses grave complications in endotracheally intubated patients in ICU’s 
worldwide.It leads to adverse clinical outcomes and increase in healthcare costs.(1) 
The causes of VAP are different among  different patient populations and also in 
different type of Intensive care units.Hence the local microbial flora associated with 
VAP and their sensitivity pattern should be studied in all clinical setting which may 
guide in the effective and rational utilization of antimicrobial agents.Our Institution 
is a tertiary care hospital providing critical carefacilities,where many patients 
routinely undergo assisted mechanical ventilation.  
The present study isundertaken to detect bacterial and fungal etiological agents 
commonly associated with VAP in our hospital Intensive care unit and  also to 
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study their antibiotic susceptibility patterns with specialemphasis on multidrug 
resistant pathogens. 
AIMS AND OBJECTIVES 
Aims: 
1. To identify the bacterial and fungal etiological agents associated with 
Ventilator Associated Pneumonia(VAP). 
2. To evaluate the antimicrobial susceptibility pattern for the isolates. 
3. To determine the frequency of Multidrug resistant (MDR) pathogens among 
the VAP patients. 
4. Toanalyse the risk factors associated with VAP. 
5. To calculate the Ventilator associated pneumonia rate per 1000 ventilator 
days. 
6. Toasses the clinical outcome in VAP patients. 
Objectives: 
1. To monitor adult patients on mechanical ventilator in Medical Intensive care 
unit for the development of VAP by clinical and radiological criteria 
2. To Process endotracheal aspirates and BAL samples quantitativelyfor the 
identification of  causative organism. 
3. To detect the presence of ESBL, AmpC beta lactamase, and (MBL) 
Metallobetalactamase  production among the MDR  pathogens. 
4. Toanalyse the risk factors for the development of Ventilator Associated 
Pneumoniaby clinical history and medical records. 
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5. To monitor the total number of patientson mechanical ventilator and the 
totalventilator days exposed by the patients inMICU. 
6. To follow up the patients with VAP for  prognosis. 
REVIEW OF LITERATURE. 
History: 
The Roman physician Galen may have been the first to describemechanical 
ventilation: "If you take a dead animal and blow air through its larynx [through a 
reed], you will fill its bronchi and watch its lungs attain the greatest 
distention.(11).Vesalius too describes ventilation by inserting a reed or cane into the 
trachea of animals(10). 
The iron lung, also known as the Drinker and Shaw tank, was developedin 1929 and 
was one of the first negative-pressure machines used for long-term ventilation. It 
was refined and used in the 20th century largely as a result of the polio epidemic 
that struck the world in the 1940s. The machine is effectively a large elongated 
tank, which encases the patient up to the neck. The neck is sealed with a rubber 
gasket so that the patient's face (and airway) are exposed to the room air.(11) 
The design of the modern positive-pressure ventilators were mainly based on 
technical developments by the military during World War II to supply oxygen to 
fighter pilots in high altitude. Such ventilators replaced the iron lungs as safe 
endotracheal tubes with high volume/low pressure cuffs were developed.The 
popularity of positive-pressure ventilators rose during the polio epidemic in the 
1950s in Scandinavia and the United States and was the beginning of modern 
ventilation therapy(11) 
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Definition: 
The exact definition of VAP is still a matter of debate ,because of  the lack of 
criteria which is able to distinguish itfrom other pulmonary conditions in patients 
who are critically ill. 
In 2005, the American Thoracic Society and InfectiousDiseases Society of America 
jointly published practicalguidelines on hospital-acquired infection which 
defines(HAP)Hospital acquired pneumonia as pneumonia that occurs 48 hours or 
more after admission, which was not incubating at the time of admission whereas 
VAP isdefined as  pneumonia that arises more than 48-72 hrs after endotracheal 
intubation.(2)The 48-hours time frame was set to differentiate any newinfection 
from processes already ongoing at the moment ofintubation. VAP is categorised 
into an early and late onsetVAP,due to the difference in epidemiological features 
and treatment options available for the two forms (2). 
Similarly, the Centers for Disease Control (CDC) defined VAP as pneumonia that 
occurs in a patient who was intubated and ventilated at the time of or within 48 hrs 
before the onset of the pneumonia.The importantdifference in the above two 
definition  is that in CDC,diagnostic criteria does not require  a window of time 
after intubation to be called as VAP.(13)This difference is relevant, because the 
CDC’s definition includes pneumonia occurring within the first 2 days of 
mechanical ventilation,whichwould be excluded using the American 
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ThoracicSociety/Infectious Diseases Society of America definition,leading to an 
increase in VAP incidence. 
Pneumonia acquired within 48 hours after hospital admission as aconsequence of 
emergency intubation, aspiration due to decreased level ofconsciousness and coma, 
or cardiopulmonary resuscitation are excluded fromdefinition of VAP .(2) 
Categorisation of VAP:(3) 
Early-onset VAP 
Ventilator associated pneumonia occurring in the first four days ofendotracheal 
intubation and initiation of mechanical ventilation is called as early onset VAP 
anditaccounts for a better prognosis. 
Late-onset VAP  
Ventilator associated pneumonia developing after four days of 
mechanicalVentilation is defined as late onset VAP andis associated with higher 
mortality and is often caused by multidrug resistant bacteria.(2) 
Incidence: 
VAP is one of the most important nosocomial infections in ICU causingsignificant 
morbidity and mortality.(12)Accurate data on the epidemiology of VAP arelimited 
by the lack of standardized criteria for its diagnosis.The incidence of VAP is 
different among various studies which depends on the definition used to diagnose 
VAP,the hospital or ICUtype,the study population  and the level of exposure to 
antibiotics.The VAP rate is higher in surgical ICUs when compared to medical 
ICU’s(13,17). 
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A study was conducted with Athenians ,which identified patients at a greater risk of 
developing VAPand the incidence of VAP among patients on mechanical ventilator 
was found to be around eight percent. 
(12)Bowton DL et al(24) (2006) showed in their study that the nosocomial 
pneumonia  rate in mechanically ventilated patients varies from 9% to 68% 
andmortality rates varies from 33% to 71%. 
Wagh H andAcharya D stated the rates of VAP to range from 9 to 27% with the 
presence ofMDR pathogens and associated with high morbidity and mortality 
rates.VAP also increased length of ICU stay by 28%.(2) 
A study from India evaluated 51 patients in the critical care unit and found a 
mortalityrate of 37% attributable to VAP, which also correlated very well with 
higher APACHEIII scores; 33% of the cases were early onset, and 67% were late 
onset.Themortalityrates of patients with or without VAP in different studies  were ; 
71% and 28% (20) 55% and 25%,(19)and 33% and 19% (21) respectively. 
There is increased risk of acquiring pneumonia when there is increase in duration of 
mechanical ventilation.(23). The prognosis for VAP caused by Gram negative 
aerobic bacilli  is considerablyworse than that for infection with Gram positive 
pathogens.According to Study by Fagon et al(20) mortality associated 
withPseudomonas or Acinetobacter pneumonia was 87% compared to 55% for 
pneumoniadue to other organisms.  
Similarly,(Kollef and coworkers)(17) demonstrated that patientswith VAP due to 
pathogens like Acinetobacter spp. ,Pseudomonas aeruginosa,  had a significantly 
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higher  mortality rate(65%) when compared to patients with VAP due to other 
organisms (31%). 
 
 
Risk factors for VAP 
During the first four days of artificialventilation , insertion of multiple central 
venous line,emergency intubation and intravenous sedatives were found to be 
independent risk factors of Ventilator Associated Pneumonia,whereas after 4 days 
of mechanical ventilation the risk factors of VAP are tracheostomy, reintubation 
and treatment with H2 receptor antagonists.(12,15) 
Host Factors: 
Surgery: 
Post surgical patients are at increased risk for the development of VAP(4).Risk for 
VAP differs among various types of surgicalICU’s.Cardiothoracicsurgery and 
trauma patients were more prone to develop VAP.(4) 
Burns: 
VAP is more common in serious thermal injury patients,especially if there is co-
existent inhalation injury or if the patient is intoxicated at the time of admission.(30) 
Sinusitis: 
Patients with infectious sinusitis are at high risk for VAP,with 67% of them 
developing pulmonary infection shortly following the diagnosis of sinusitis.(4). 
Immunosuppression: 
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 Patients who areimmunosuppressedfrequently develop pulmonary infectious 
complications leading to respiratory failure,which necessitate mechanical 
ventilation.Immunocompromised patients are at risk fordeveloping  VAP due to 
opportunistic microbes as well as the common pathogens.(30) 
 
Intervention factors: 
Intubation: 
Intubation is the most important risk factor associated with a 3 to 21 fold risk for 
developing VAP.It increases the risk by: 
1.causing trauma to nasopharynx or oropharynx 
2.impairing swallowing of secretions 
3.Increasing bacteriological adherence and colonization 
4.causing ischemia secondary to cuff pressure 
5.impairingciliary clearance and cough 
6.causing pooling of contaminated secretions and leakage of secretions around the 
cuff. 
7.requiring frequent suctioning.(31) 
Tracheostomy and reintubation: 
Aspiration during reintubation and the presence of tracheostomy may contribute to 
the development of VAP.(29,34) 
Nasal intubation: 
Nasal intubation increases the risk of VAP by blocking the nasal ostia and 
promoting the development of sinusitis which act as a source of VAP pathogen.(34) 
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Duration of mechanical ventilation: 
The incidence of VAP increases with duration of mechanical ventilation.The risk of 
VAP is highest early in the course of hospital stay and is estimated to be 3% per day 
in the first week of MV,2% per day in the second week and 1% per day later(32).As 
mechanical ventilation is most often short term,about half of all episodes of VAP 
are of early onset type(4). 
Nasogastric tube: 
Nasogastric tube may increase oropharyngeal colonization and cause stagnation of 
secretions.It also increases gastro-esophageal reflux and hence the risk of 
aspiration.(4,33) 
Supine position: 
Seriously ill patients who spend greater time at backrest elevations of less than 300 
during the first day of intubation are more prone to develop VAP.(34) 
Antacids: 
Patients receiving H2receptor antagonists were at high risk for developing VAP(4). 
Prior antibiotic therapy: 
Prior antibiotic therapy appears to have an interesting dual effect.Thoughthe  use of 
antibiotics prophylactically reduces the risk of early onset VAP (due to antibiotic 
susceptible bacteria),it may predispose to late onset VAPdue to colonization and 
infection with multi drug resistant pathogens.(4,31,30) 
Respiratory equipment: 
Respiratory equipment itself may act as a source for bacteria responsible for VAP. 
In 104 mechanically ventilated patients,Closed versus open suctioning systems were 
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compared and VAP rate was found to be lowerin patients treated with the closed 
system when compared with those patients with the open system .(35,36) 
 
 
Mechanical ventilators with humidifying cascades  have high levels of tubing 
colonization as well as condensate formation that may be a risk factors for 
pneumonia.(37) 
As most of the tubingcolonization was derived fromsecretions of the patients, the 
highest bacterial counts wereseen near the endotracheal tube. 
The use of heat-moisture exchangers (HMEs) has been studied by various studies in 
placeof conventional heated-water humidification systems. 
HMEs are associated with lower incidence of VAP than heated 
humidifiers(38).(Lorente L et al )(39) suggests that using HMEs instead of heated 
humidifiers, may increase the VAP rate.  
Kollef MH et al (40) suggested improper hand washing results in 
crosscontamination of patients  which is the major personnel related risk factor for 
VAP. Patientswho are in mechanical ventilation often need interventions such 
assuctioning of secretions or manipulation of the ventilator circuit. 
Failure inadherence to proper hand washing techniques and not changing the gloves 
while handling manycontaminated patients has been associated with an increase in 
VAP rate. 
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Etiological agents: 
Microorganisms  causing VAP may differ according to the specificdiagnostic 
methods used ,populationunder study, the durations of  stay in hospital and ICU’s. 
The type of organism causing VAP usually depends on mechanical 
ventilationduration.Early onset VAP is caused by antibiotic sensitive pathogens, 
whereas late onset VAP is caused by multi drug resistant pathogens.  
 Bacteria causing early onset VAP areHemophilusinfluenzae, Streptococcus 
pneumoniae,methicillin-sensitiveStaphylococcusaureus(MSSA),Escherichia 
coli,Proteusspecies,Klebsiellapneumoniae,Enterobacter species,and 
Serratiamarcescens. 
MDR bacteriasuch asmethicillin-resistant S. aureus(MRSA), Acinetobacter sp., 
Pseudomonas aeruginosa, and extended-spectrum beta-lactamase producing 
bacteria (ESBL) are typically pathogens of late onset VAP (33) 
Oropharyngeal commensals likeStreptococcus viridans, Corynebacterium, 
coagulase negative staphylococcus (CONS) and Neisseriaspecies can attain 
clinically significant numbers in the lower airways. 
Candida albicansand other Candidaspecies can be isolated commonly from 
endotracheal aspirates, but usually it representscolonization of the airways, rather 
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than pneumonia inimmunocompetentpatients.It rarely requires antifungal 
therapy.(2) 
Multidrug resistant pathogens: 
The pathogens  causing ventilator associated pneumonia like 
Acenetobactersp,pseudomonassp,(nonfermentors) and other GNB‘s producing 
ESBL, AmpCbetalactamases, display high levels of resistance to antibiotics.These 
bacteria are called as multidrug resistant pathogens.(3) 
Pathogens causing VAP, their frequency and their possible mode of multi drug 
resistance, if any, are listed below (2)–(4): 
1. Pseudomonasspecies(24.4 %): (Upregulation of efflux pumps, decreased 
expression of outer membrane porinchannel, acquisition of plasmid mediated  
metallobetalactamases). 
2.Staphylococcusaureus(20.4 %, of which > 50 % MRSA): Production of a 
penicillin-binding protein (PBP) with reduced affinity for beta-lactam antibiotics. 
Encoded by the mecA gene. 
3. Enterobacteriaceae (14.1 % – includes Klebsiella spp., E. coli, Proteus 
spp.,Enterobacter spp., Serratia spp., Citrobacter spp.): Plasmid mediated 
production of ESBLs, plasmid mediated AmpC-type enzyme. 
4. Streptococcusspecies (12.1 %). 
5. Hemophilusspecies (9.8 %). 
6.Acinetobacterspecies(7.9  %): Production of metalloenzymes or carbapenemases. 
7. Neisseriaspecies (2.6 %). 
8. Stenotrophomonasmaltophilia(1.7 %). 
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9. Coagulase-negative staphylococcus (1.4 %). 
10. Others (4.7 % – includes Corynebacterium, Moraxella, Enterococcus, fungi). 
 
 
 
Pathophysiology: 
VAP occurs by four main routes: 
1.Aspiration of infectious secretions,either directly from the oropharynx or 
secondarily,by reflux from the stomach, 
2.Inhalation of contaminated air or infectious aerosols 
3.The development of biofilm acts as a bacterial reservoir for inoculum in to lung. 
4.Hematogenous spread of microbes to the lung from a distant focus of infection. 
The inspired air is filtered and humidified in the upper airways.The presence of 
antimicrobial agents in saliva ,an intact mucociliary clearance and cough reflex acts 
as a normal defence mechanism in the host to prevent invasion of bacteria.In ICU 
patients who are critically ill,these defences are altered which favours the pathogens 
to reach the distal lung and  multiply to cause an invasive disease.(4). 
A well structured biofilm develops rapidly within hours of tracheal 
intubation.Bacteria easily attach to the polyvinychloride (PVC) surface of the ETT, 
where they multiplyand differentiate their phenotype within the extracellular self-
produced matrix (8).  
The most common organisms which are associated with biofilm formation are Gram 
negative bacterialand fungal organisms. The organisms can colonize the 
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endotracheal tube atthe moment of intubation due to leakage of secretions outside 
the cuff, or following Endo tracheal suctioning. 
There is increased bacterial resistance to antimicrobial agents due to biofilm 
formation, which is probably related todifferent cellular and extracellular 
mechanisms. 
Biofilm can act as a reservoir for highly infectivemicroorganisms that can detach 
themselves and enter the lungs as aconsequence of endotracheal aspiration or 
inspiratory flow during mechanical ventilation.(8). 
Diagnosis: 
Clinical diagnosis: 
The clinical diagnosis of VAP is made when a radiographic infiltratethat is 
progressive or new plus at least 2 of the following 3parameters-leukocytosis, 
orfever or purulent tracheal secretions. 
An alternative approach to diagnose VAP clinically is suggested byPugin et 
al.,based on fever, leukocyte count, purulent tracheal secretions,difference in 
oxygenation, radiographic changes, Gram stain and culture results is calculation of 
Clinical Pulmonary Infection Score (CPIS).(37,38). 
A CPIS of more than 6 was associated with a clinical definition of pneumonia 
which has 93% sensitivity and 100% specificity  compared withquantitative BAL 
culture. 
Modified CPIS is suggested by Singh et al. who used first five clinical variables to 
diagnose  VAP initially, then after 72 h recalculate CPIS based on all the six clinical 
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variables,whichhelps to stop antibiotics in those patients with a (CPIS<6)a low 
scorepersistently after three days of treatment.(39). 
Fartoukh et al(2) suggested that Gram stain results should be incorporatedinto the 
score which increase CPIS sensitivity. 
 
 The Clinical Pulmonory Infection Score (CPIS) Ref(1) 
Assessed Parameter Result Score 
Temperature ≥38.5°C & ≤ 38.9°C Point 1 
>39°C or <36°C Point 2 
Blood leucocyte count 
(cells/mmᶾ) 
<4000 or >11000. Point 1 
+ >50% band forms Point 2 
Oxygenation(mmHg) Pa02/Fio2 <240 and no ARDS Point 2 
Chest X-ray No infiltrates Point 0 
Patchy or diffuse infiltrates Point 1 
Localised infiltrates Point 2 
Tracheal secretions 
(subjective visual scale) 
Mild/non purulent Point 1 
Purulent Point 2 
Culture & Gram stain of 
endotracheal aspirate. 
Moderate or heavy growth Point 1 
Same morphology on Gram 
stain 
Point 2 
 
Radiological diagnosis: 
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The findings in chest radiograph(eg.progressiveinfiltrate,rapidcavitation,single air 
bronchogram etc.) were associated with a specificity of 96% for diagnosis of VAP. 
Specific findings in radiograph are relatively uncommon, help in excluding the 
VAP diagnosis,when it is normal(7). 
Other conditions like emphysema, chemical 
pneumonitis,cardiopulmonaryedema,drug reaction, pulmonary contusion,atelectasis 
etc. may show similar radiographic abnormalities consistent with VAP.(7,4,33) 
Laboratory diagnosis: 
The microbiological diagnosis is based on  microscopy and  culture of  secretions 
obtained from the lower respiratory tract(41) as suggested below. 
1)The samples should be collected preferably before starting antibiotics. 
2) Adequate amount of sample is essential. 
3) Specimenprocessing within 30 min is ideal,otherwiserefrigerated in case of delay 
of few hours.(4,41,42). 
 Microscopy: 
The  DirectGramstain is used to detect bacteria as well as yeast cells insamples from 
respiratory tract.The presence of greater than 10 squamous epithelial cells per low 
power field in gram stain is used to reject the endotracheal aspirate sample from 
processing.The number of pus cells is generally not indicative of a good specimen 
in patients with VAP(43,44). 
The presenceof pus cells is not specific for a culture to be positive,but inthe absence 
of leucocytes, a positive culture is unlikely and  it also representsinadequate 
sampling(15). 
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Culture: 
Qualitative culture: 
There is high possibility of false positivity in Qualitative endotracheal 
aspirateculture .This is because of the growth of lower respiratory tract 
colonizers.(31)It is used to rule out the VAP diagnosis if negative culture is 
obtained.(15) 
The treatment based  only on qualitative culture report will result in unnecessary 
overuse of antibiotics.(46,47) 
Semiquantitative culture: 
Semiquantitative culture is performed based on the four quadrantstreak technique 
using a calibrated loop. Endotracheal aspirate (ETA)cultures are read 
semiquantitativelybyobservingthe growthin thefourquadrants, which suggests the 
approximate number of CFU/ml of thebacteria in the specimen(46).In a study 
comparing the semiquantitative culture (calibrated looptechnique) and the 
quantitative culture (serial dilution technique) of121 BAL samples, a very good 
agreement between the techniques wasobserved with only one discordant 
result[52]However, use of semiquantitative cultures for guiding antibiotictherapy 
may be associated with substantially more patients beingovertreated as observed in 
a study by Brun-Buisson et al(46). 
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Quantitative culture: 
Quantitative culture is done by serially diluting the specimen.Culturereportsare 
given innumber of colony forming units per milliliter (CFU/ml).If it is more than 
the threshold value,it is diagnosed as pneumonia. The commonly used threshold 
values for diagnosis of VAP by quantitative culture are≥105for ETA,≥104for 
BAL,and≥103CFU/ml for PSB, respectively(4,48)Quantitativecultures are  
preferredfor making decisions regarding treatment of VAP. 
Bronchoscopic specimens: 
TheBAL and protected specimen brush (PSB) are the commonly used 
bronchoscopictechniques .(4) In critically ill patients ,there is mild risk for 
development of hypoxemia, cardiac arrhythmias, and bronchospasm(4). 
Non bronchoscopic specimens- Endotracheal aspirates: 
Endotracheal aspirates(ETA) cultured quantitatively is a good method to diagnose 
VAP asit is an non invasive approach which is inexpensive and can be used 
widely.(15). 
Non-bronchoscopic vs. bronchoscopic specimens: 
Quantitatively cultured Endotracheal aspirate and bronchoscopically collected 
specimens have a very good correlation. 
Role of blood and pleural effusion cultures: 
Though the organisms recovered from blood and pleural fluidis considered 
significant in VAPpatients,it has limited role in diagnosis because in only less than 
10% VAP patients, spread occurs to blood and pleural space.(4) 
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The blood culture  has a sensitivity of only 26%fordiagnosing the 
VAPpathogens.(49).Hence it is recommend to take blood and pleural effusion 
culturesin suspected VAP patients,when unable to find the other source of 
infection(4). 
Role of biomarkers as diagnostic and prognostic markers of VAP: 
 Biomarkers likeprocalcitonin (PCT),C-reactive protein(CRP),endotoxin, soluble 
triggering receptor expressed on myeloid cells-1 (sTREM-1) are used as 
diagnosticbiomarkers whereas  proadrenomedullin, endothelin-1 precursor peptides  
andcortisol levels are used as prognostic markers.(50). 
Treatment: 
The guidelines suggested by American Thoracic Society forVAP treatment depends 
on the presence or absence of risk factors for MDR pathogens which is summarized 
below.(2). 
Initial Empirical Treatment for VAP(2) 
VAP without any risk factors for 
MDR pathogens 
 VAP associated with risk factors for 
MDR pathogens 
 
Ceftriaxone 
 
AntipseudomonalCephalosphorin(Cefipime
,Ceftazidime) 
Or 
 
Or 
Levofloxacin,Moxifloxacin or 
Ciprofloxacin 
 
AntipseudomonalCarbapenem(Imipenem 
or Meropenem) 
Or 
 
Or 
Ampicillin/Sulbactum 
 
Or 
 
Beta Lactum/Beta lactamase 
inhibitor(Piperacillin-Tazobactum) 
Plus 
Ertapenem Antipseudomonalfluoroquinolone 
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The durationof empiric antibiotic therapy is traditionally fourteen to twenty one 
days,maybe shortened in those patients with  good clinical recovery to7 days, 
except in case of infection withnonfermenters especiallyPseudomonas aeruginosa 
and Acinetobacterspecies.(3) 
Initial Intravenous adult dose of antibiotics for empiric therapy of VAP with 
late onset disease or risk factors for MDR pathogens(2) 
 
Antibiotic Dosage * 
AntipseudomonalCephalosphorin   
Cefipime 1-2 g every 8-12 h 
Ceftazidime 2g every 8h 
    
AntipseudomonalCarbapenam   
Imipenem 500mg every 6h or 1g every 8h 
Meropenem 1g every 8h 
    
Beta Lactum/Beta lactamase 
inhibitor   
Piperacillin-Tazobactum 4.5 g every 6h 
    
Antipseudomonalfluoroquinolone   
Ciprofloxacin 400mg every 8h 
Levofloxacin 750mg every day 
    
Aminoglycoside   
Amikacin 20mg/kg per day 
  
  
  
  
  
  
  
  
  
  
(Ciprofloxacin or Levofloxacin) 
Or 
Aminoglycoside 
(Amikacin,gentamicinorTobramicin) 
Plus 
Linezolid or Vancomycin 
(In MRSA infection.) 
MDR=Mutidrug resistant, MRSA=Methicillin-resistant staphylococcus aureus 
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Gentamicin 7mg/kg per day 
Tobramicin 7mg/kg per day 
    
Linezolid 600mg every 12h 
Vancomycin 15mg/kg every 12h 
    
MDR=Multidrug resistant. 
*Dosages are based on normal renal and hepatic function. 
 
 A new approach based on‘de-escalation’strategyhasbeen suggested for effective 
treatment without the antibioticoveruse.(51) 
The use of clinical and microbiological data to change from an initial broad 
spectrum treatment to therapy witha narrower spectrum agents and withfewer 
antibiotics is referred as (51).In a study evaluating the nebulized colistin treatment, 
it is found to be safe and effective for treating Multi drug resistant organisms like 
Acinetobacterbaumannii and pseudomonas aeruginosa.(52). 
Prevention of VAP: 
There are multiple recommended measures for prevention of VAP.These measures 
are summarized below(1). Institutions or ICUs may observe a reduction in VAP 
rates by utilizing a ‘VAP-bundle’ approach. (54,55,57,58). 
Suggested measures for prevention of ventilator-associated pneumonia- (1,56) 
S.no. ICU focused measures  
 
Institution focused measures 
 
1 Alcohol-based hand washing 
policy . 
Surveillance program for pathogen profiling 
and creation of “antibiogram” 
2 Early discontinuation of 
invasive devices  
Frequent educational programs to 
Reduce unnecessary antibiotic prescription. 
3 Reduce reintubation rates Propagate use of non-invasive positive 
pressure ventilation(NIPPV) 
4 Use of oropharyngeal vs. 
nasopharyngeal feeding tubes  
 
Endotracheal tubes (ETTs) with potential 
benefit 
Polyurethane-cuffed ETT 
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Silver/antibiotic coated ETT 
Aspiration of subglottic secretions. 
5 Semi-recumbent patient 
positioning (30–45°)  
Maintain policy for oral decontamination, 
Selective digestive decontamination (SDD) 
6 Endotracheal tube cuff 
pressure ~ 20 cm H2O  
Early weaning and extubation 
 
7 Small bowel feeding instead 
of gastric feeding  
Daily sedation holds 
 
8 Prophylactic probiotics  
 
Preference on using heat-moisture 
exchangers over heater humidifiers 
 
9 Early tracheostomy  
 
Mechanical removal of the biofilm (e.g., the 
mucus shaver) 
 
The 5-element (Institute of Healthcare Improvement)IHI VAP bundle (57).includes: 
1.oral care with chlorhexidine 
2.Head of bed elevation,  
3.stress ulcer prophylaxis, 
4.daily sedation assessment and spontaneous breathing trials. 
5.deep venous thrombosis prophylaxis. 
Implementation of VAP prevention bundle significantly reduce  VAP rates, 
antibiotic use and MRSA acquisition (53). 
The IHI emphasizes the need for high (95 %) overall compliance rates with VAP 
bundles although this particular study reported overall bundle compliance rates of 
70%. 
A single-dose of antibiotics within four hrs of intubation may be effectivein a cohort 
of comatose patients in preventing early onset VAP  (59).  
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MATERIALS AND METHODS: 
Ethical consideration: 
This study was approvedbyinstitututionalethicscommittee and informed consent was 
obtained from the study population. 
Study design: Cross sectional study. 
 
Study period: The study period is from October2014 to August 2015 
Study setting:  
The study was conducted at the Institute of Microbiology, Madras Medical College 
in association with other Departments (Intensive Medical Care Unit 
(IMCU)&Toxicology Unit) of Rajiv Gandhi Government General Hospital, 
Chennai. 
Sample size: 100 patients 
Study population: 
The study was done in patients on ventilatory support for more than 48hrs in the 
IMCU & Toxicology Unit with the following inclusion criteria. 
Inclusion criteria: 
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 Patients older than 18 years. 
 Patients undergoing mechanical ventilation for more than 48hrs,with the 
radiological and clinical parameters indicative of Ventilator Associated pneumonia. 
(The parameters are presence of a new or progressive radiographic infiltrate plus 
atleast two of the following features which include fever greater than 
38C̊,leucocytosis or leukopenia and purulentlower respiratory secretions)(2) 
 
Exclusion criteria: 
 Patients who are severely immunocompromised such as Acquired immune 
deficiency syndrome(AIDS), organ transplant patients, terminal stages of 
malignancy are excluded. 
 Patients with pneumonia prior to mechanical ventilation or within 48 hours of 
Mechanical ventilation.(2) 
Data collection 
The various patient data such as age, gender,address, date of admission ,level of 
consciousness,risk factors(presence of nasogastric tube,enteralnutrition,antacid or 
histamine type 2(H2) blocker therapy) involved, underlying diseases, date of 
intubation/ tracheostomy, duration of mechanical ventilation, prior antibiotic 
therapy etc.wererecorded.The clinical condition ofpatientswasfollowed up from the 
time of inclusion in the study to the date of discharge from MICU& Toxicology 
unit. 
Sample Collection,Transport and processing: 
Samples collected: 
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1.Endotracheal Aspirate 
2.Bronchioalveolar lavage. 
3.Blood. 
Under strict aseptic precautions,samples were  collected from the patients and 
transported immediately to the laboratory in appropriate settings and sample 
processing  done. 
 
Collection of Endotracheal aspirates(ETA): 
Under aseptic precautions endotracheal aspirates were obtainedusing a 22-
inch,No.12F suction catheter and collected in a mucus collector. The catheter was 
gently introduced through the endotracheal tube for at least 25-26cmlength.Gentle 
aspiration was then performed without instilling saline and the catheter was 
withdrawn from the ET tube, 2mL of normal saline was injected  with a sterile 
syringe to flush the exudate into a sterile container for collection.(16) 
Collection of Broncheoalveolarlavage(BAL): 
During this procedure,a high volume of saline (100 to 300ml) was infused in to a 
lung segment through a bronchoscope by bronchoscopist,to obtain cells and proteins 
of pulmonary interstitium and alveolar spaces.It is estimated that more than one 
million alveoli are sampled during this process.The saline is then aspirated in a 
sterile containerand sent for microbiological processing.(60) 
Processing of samples: 
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Respiratory(ETA&BAL) Samples were mechanically homogenised by vortexing  
for 1 min and then subjected to the following microscopic examination using 
standard laboratory techniques.(62) 
Microscopy : 
Direct Gram stain: 
Direct examination of Gram stained preparations were performed and studied for 
the presence of squamous cells, polymorphonuclearcells,bacteria(Gram positive and 
Gram negative) and their morphology. 
 For Gram stain results, the thresholds for the diagnosis of VAP with the ETA 
samples were as follows:(5) 
 >10 polymorphonuclear neutrophils (PMN) / high power field (HPF) 
 ≥ 1 bacteria / oil immersion field . 
 presence of intracellular bacterial inclusions. 
Criteria used to reject endotracheal aspirates from adult patients by Gram’s 
stain:(60) 
1.Greater than 10 squamous epithelial cells per low power field.    
2.No organism seen under oil immersion field. 
KOH mount: 
10% potassium hydroxide (KOH) mount is performed for the identification of 
fungal pathogens.(60) 
Culture: 
Endotracheal aspirate (EA) /BAL specimenswere processed quantitatively for the 
identification and categorisation of pathogens and colonizers.Specimenswereserially 
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diluted with sterile normal saline as 1/10dilution, 1/100dilution, 1/1,000 dilutions 
and 0.01 ml of above dilutions were inoculated on to 5% sheep blood 
agar,Macconkey agar and Chocolate agar. After incubation at 37̊C  for 24 to 48 
hours,colony count was done and expressed as number of colony forming units per 
ml (CFU/ml).(18). 
The number of bacteria in the original sample is expressed in colony forming unit 
per millilitre.(cfu/ml)=number of colonies ×dilution factor×Inoculation factor. 
 
Bacterial growth with a colony count ≥105 CFU/ ml (for Endotracheal aspirate) and 
≥10⁴cfu/ml(for BAL) were  considered aspathogens.Growth of any organisms 
below the threshold were categorised as colonizers or contaminants.(4,16). 
The plates whichshowed threshold growth were studied by colony morphology, 
Gram reaction and identified using standard biochemical reactions.Afterinitial 
characterisation of the isolates by colony morphology and Gram stain, species 
identification and susceptibility testing were done. 
The sample was also inoculated on to two tubes of Sabouraud’s dextrose agar and 
incubated at 25°C and 37°C.The slants were inspected daily during the first week 
and twice weekly during the next three weeks for growth. 
The macroscopic appearance of the colonies in SDA were studied and the yeast 
isolates wereidentified by Gram’s stain morphology andgerm tube test. 
Blood culture:(62). 
Under strict aseptic precautions, venepuncture site was cleaned with 70% alcohol 
and then with 2 % Povidone Iodine. The disinfectant was allowed to act for 1 
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minute and then 10ml of blood sample was collected with a sterile syringe and 
added into a sterile screw capped blood culture bottle containing 50 ml of sterile 
Brain Heart Infusion broth(BHI broth) at the bed side and transported immediately 
to the laboratory. 
Brain Heart Infusion (BHI) Broth was incubated at 37°C aerobically and examined 
for turbidity at 24 and 48 hours. If turbidity or haemolysis was observed in BHI, 
subcultures were done onto Blood Agar and MacConkey Agar. 
These plates were incubated aerobically at 37°C for 24 hrs. Any growth observed 
was identified up to species level by colony morphology, Gram staining, catalase 
test, oxidase test, motility and biochemical reactions.Subcultures were done every 
third day for a period of 10 days and a negative report was given if no growth was 
observed. 
Interpretation of clinical and microbiological Criteria: 
The patients satisfying both the clinical and microbiological criteria were diagnosed 
with VAP.(18,22)Modified clinical Pulmonary infection Score >6  
Positive Gram stain  (more than 10 polymorphonuclear cells/high power field and ≥ 
1 bacteria per oil immersion field) and quantitative endotracheal aspirate culture 
results showing ≥105CFU/ml. 
VAP pathogenswere identified as follows: 
Identification of the organisms were done by various  biochemical tests like  
Catalase test, Oxidase test, Coagulase test, Nitrate reduction test, Indole test, Methyl 
red test,VogesProskauer test, Citrate utilization test, Urease test,Triple sugar iron 
agartest,Mannitol motility test and by standard bacteriological procedures.(62) 
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Gramnegative bacilli producing bluegreenpigment,Nonfermenting, motile, oxidase 
positive, nitrate reducing, were identifiedasPseudomonasaeruginosa. 
Gramnegativecoccobacilli ,Nonfermenting, non motile, oxidase negative, nitrate 
non-reducing, producing acid from OF glucose and 10% OF lactoseoxidatively, 
growth at 42̊ C, were identified as Acinetobacterbaumannii. 
Gramnegative bacilli, fermenting glucose and othercarbohydrates,Oxidasenegative, 
catalase positive, nitrate reducing, nonspore forming, were identified as members of 
Enterobacteriaceae.  
Gram-positive cocci in clusters, with characteristic golden yellow 
pigment,Catalasepositive, mannitol fermenting, coagulase producing were identified 
as Staphylococcus aureus. 
Anti microbial  susceptibility testing: 
Anti microbial  susceptibility testing is done by Kirby Bauer’s disc diffusion 
method  0n Mueller Hinton agar based on CLSI guidelines.(62,63) 
Preparation of inoculum for sensitivity testing: 
A single colony of the test organism was picked up with sterile loop and suspended 
in saline and incubated at 37 ̊ C for 2 hrs.The turbidity of the suspension was 
adjusted to 0.5 McFarland’s standard(1.5x108 CFU/ml).The liquid culture of the test 
isolate adjusted to 0.5 McFarland turbidity was spread on the surface of Mueller 
Hinton agar plate.The plates were incubated at 37 ̊C overnight.The zone of 
inhibition was measured and interpreted as per CLSI (Clinical Laboratory Standards 
Institute ) guidelines.The antibiotic discs were procured from Himedia,Mumbai and 
quality check done with the following control strains- 
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Escherichia coli(ATCC 25922),Pseudomonas aeruginosa(ATCC 
27853)andStaphylococcusaureus (ATCC 25923) 
 
 
 
Panel of antibiotics included for testing antimicrobial sensitivity of Gram 
negative bacilli.(63) 
Antibiotic  (Disc content ) 
Diameter of Zone of inhibition in mm.  
Sensitive  Intermediate  Resistant  
Amikacin  (30 µg) ≥ 17  15-16 ≤ 14 
Cefotaxime (30 µg) 
Enterobacteriaceae 
Acinetobacter sp. 
      
≥26 23-25 ≤22 
≥23 15-22 ≤14 
Ceftazidime (30 µg) 
Enterobacteriaceae 
P.aeruginosa&Acinetobacter sp.  
   
≥21 18-20 ≤17 
≥18 15-17 ≤14 
Cotrimoxazole (1.25 μg / 23.75 μg)  ≥16 11-15 ≤10 
Ciprofloxacin (5 μg) ≥21 18-20 ≤17 
Gentamicin (10 μg) ≥15 13-14 ≤12 
Imipenem (10 μg) 
Enterobacteriaceae 
P.aeruginosa 
Acinetobacter sp.  
      
≥23 20-22 ≤19 
≥19 16-18 ≤15 
≥16 14-15 ≤13 
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The panel of antibiotics included in the antimicrobial sensitivity testing for 
Staphylococcus aureuswere .(63) 
Antibiotics  Disc content Zone of inhibition in mm 
  Sensitive Intermediate Resistance 
Amikacin 30μg  ≥17 15-16 ≤14 
Gentamicin 10μg ≥15 13-14 ≤12 
Ciprofloxacin  5μg  ≥21 16-20 ≤15 
Cotrimoxazole 1.25/23.75μg  ≥16 11-15 ≤10 
Chloramphenicol  30μg  ≥18 13-17 ≤12 
Penicillin  10units  ≥29 - ≤28 
Erythromycin  15μg  ≥23 14-22 ≤13 
Tetracyclin 30μg  ≥19 15-18 ≤14 
Cefoxitin 30μg  ≥22 - ≤21 
The VAP  pathogens were screened for the production of  (ESBL) Extended 
spectrum beta lactamases. 
Extended spectrum ß- lactamase (ESBL) detection method: 
Meropenem(10μg) ≥ 18 15-17 ≤14 
Piperacillin- Tazobactam (100 μg/10 μg) ≥21  18-20  ≤17  
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Gram negative bacilli ( Enterobacteriaceae family) showing reduced zone of 
inhibition around Ceftazidime(30μg) &Cefotaxime(30μg) discs were further 
confirmed by combination disc method. 
Antibiotic Zone diameter for ESBL producing strain 
Ceftazidime(30μg) ≤22mm 
Cefotaxime(30μg) ≤27mm 
Phenotypic confirmation method:  
Combination disc test: 
Procedure:  
Using a sterile loop, four or five colonies of similar morphology were picked up, 
inoculated to peptone water & incubated at 37° C for 2-4 hours until turbidity 
matched that of McFarland 0.5 turbidity standard (1.5 x 108cfu/ml) . Lawn culture 
was done on Mueller-Hinton agar plates and antibiotic disc ceftazidime(CAZ 30µg) 
and ceftazidime /clavulanic acid (CAZ/CA 30µg/10µg) discs were placed on to the 
plate. 
Interpretation : 
Zone of inhibition was measured around the disc.Anincrease of≥5mm in zone of 
inhibition in a disc containing clavulanic acid compared to the drug alone is 
considered as ESBL producer.(63) 
AmpC beta lactamase enzyme detection:(64,65) 
Screening method: 
A 0.5 Mcfarland of the test isolate was swabbed on MHA plate and disc of 
cefotaxime(30µg),Ceftazidime(30μg) were placed adjacent tocefoxitin(30µg) at a 
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distance of 20mm from each other.Afterincubation,isolatesshowing blunting of 
ceftazidime or cefotaxime zone of inhibition adjacent to cefoxitin disc or showing 
reduced susceptibility to either of the above drugs andcefoxitin(30µg) were 
considered as “screen positive” and selected for detection of AmpC β-lactamases by 
AmpCdisc test. 
 
AmpC Disc Test: 
A lawn culture of E. coli ATCC 25922 was prepared on MHA plate. Sterile discs 
(6mm) were moistened with sterile saline (20μl) and inoculated with several 
colonies of test organism. The inoculated disc was then placed beside a cefoxitin 
disc (almost touching) on the inoculated plate. The plates were incubated overnight 
at 37°C. A positive test appeared as a flattening or indentation of the cefoxitin 
inhibition zone in the vicinity of the test disc. A negative test had an undistorted 
zone.  
Metalloß lactamase ( MBL) detection method: 
Screening  for MBL: 
Isolates resistant tocarbapenem(Imipenem or Meropenem)were further subjected to 
confirmatory tests for MBL detection. 
Imipenem-EDTA combined disc test:(66) 
Two to three identical colonies of the test organism were inoculated into salineand 
incubated at 37° C for 4 to 6 hours to obtain optical density matching that of 
0.5McFarland turbidity standards.  
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This suspension of test organism was then inoculated on to Mueller-Hinton Agar 
(MHA) plates by performing lawn culture with a sterile cotton swab.Imipenem 
(10µg) disc and (10 µg)Imipenem disc containing 750 µg of EDTA were placed 
20mm apart in the plate. 
Afterovernight  incubation at 37°C,enhancement of the zone of inhibition of Imp-
EDTA combination disc of ≥7mm when compared to Imipenem disc alone was 
interpreted as a positive result(MBL production). 
Modified Hodge Test:(63) 
Two to three identical colonies of Escherichia coli (ATCC 25922) were inoculated 
into saline and incubated at 37° C for 4 to 6 hours to obtain optical density matching 
that of 0.5 McFarland turbidity standards. 
A lawn culture of  E.coli ATCC 25922 was done on to the Mueller-Hinton Agar 
(MHA) plates with a sterile cotton swab. A 10μg Meropenem disc was placed at the 
centre and the test organism was streaked in a straight line from the edge of the disc 
to the edge of the plate. The plate was incubated overnight at 37° C.  
The presence of distorted zone of inhibition or clover leaf type of indentation at the 
intersection of the test organism and E.coli 25922, within the zone of inhibition of 
the Meropenem susceptibility disc was interpreted as positive result. 
METHODS FOR DETECTION OF MRSA: 
Cefoxitin disc method:(63) 
0.5 Mcfarland’s suspension of test isolate and Staphylococcus aureus ATCC 25923 
was lawn cultured on cation adjusted MHA plates separately. 30μgcefoxitindisc was 
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placed on the surface of lawn culture of both isolates and incubated at 33–35 °C in 
ambient air for 16–18 hours.  
The Interpretation was done as follows: 
For Staphylococcus aureus: 
Zone of inhibition :≥22mm-MSSA (mec A negative) 
Zone of inhibition :≤21mm-MRSA(mec A positive) 
 
 
 
MINIMUM INHIBITORY CONCENTRATION BY EPSILOMETER TEST 
(E-TEST): (62) 
All MRSA isolates were subjected to MIC estimation for Vancomycin, by using E-
test(Epsilometer) method (HI-MEDIA).  
The E-test strips contains antimicrobial agent with a continuous exponential 
gradient of antibiotics immobilized on paper material and MIC values printed on 
both sides identically. 
Procedure:  
The strains were inoculated into tubes containing 2ml of peptone water. The 
suspension was streaked onto the Mueller Hinton Agar with 2% Nacl to give a lawn 
culture. E-test strips were placed on the inoculated plates.The plates were incubated 
at 37°C for 24 hours and reading was taken the next day.  
MIC of the drug was taken at the point where the ellipse intersects the MIC scale on 
the strip. Control strain ATCC Staphylococcus aureus25923 were tested in parallel.  
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MINIMUM INHIBITORY CONCENTRATION BY MACROBROTH 
DILUTION METHOD:(for vancomycin and meropenem) 
Preparation of stock antibiotic solution: (62) 
Antibiotic stock solution was prepared using the formula   
1000 × V × C = W. 
  P 
Where P= potency of the antibiotic in relation to the base.  
(For vancomycin, P= 950/1000 mg; Himedia)   
(For Meropenem, P=750/1000mg) 
V = volume of the stock solution to be prepared (10ml)  
C =final concentration of the antibiotic solution (1024μg/ml)  
W = weight of the antibiotic to be dissolved in the volume V. 
  In a sterile screw capped bottle,10ml of distilled water is taken and the appropriate 
weight of drug (eg.vancomycin,Meropenem) is added to prepare stock solution with 
a final concentration the of antibiotic solution as 1024 μg/ml. 
Inoculum preparation for the test and ATCC control strain: 
 To 9.9 ml of Mueller Hinton broth in a sterile container , 0.1 ml of 0.5 Mcfarland 
turbidity matched test organism was added and mixed well.Similarly ATCC control 
strain inoculum was prepared. 
Procedure: 
Two rows of 13 sterile plugged test tubes were arranged in the racks. Using a fresh 
pipette, 1ml of peptone water was added to all the tubes starting from 1st to 
13thtube.The contents of the container with stock solution were mixed thoroughly 
and using a sterile pipete,1ml of the stock solution was transferred to first tube in 
38 
 
each row,mixedwell and from this concentration(512µg/ml), 1ml was transferred to 
the second tube (256µg/ml) ,then it is serially diluted till the last row.The various 
concentration of antibiotics in the following tubes are 128,64,32,16, 8, 4, 2, 1, 0.5, 
0.25, 0.125(µg/ml).Using sterile pipette, 1 ml of the above inoculum was transferred 
to each antibiotic containing tubes in the first row and also to the growth control 
tube. 
The first row of tubes were inoculated with test organism. 
The secondrow of tubes were inoculated with ATCC control strain. 
ATCC Pseudomonas aeruginosa 27853 was used as the control strain for testing 
Meropenem.ATCCStaphylococcus aureus25923 was used as the control strain for 
testing Vancomycin.  
1 ml of the antibiotic free broth was placed in the last tube in each row as growth 
control.  
1 ml of antibiotic solution were kept as sterility control.  
These tubes were incubated at 37°C overnight. 
Observation &Interpretation:  
The MIC of ATCC control strain were observed, they were within sensitive range, 
hence the test was considered to be valid. The lowest concentration of the antibiotic 
in which there was no visible growth was taken as the MIC of the drug for the test 
organism.  
Interpretation:Minimum Inhibitory Concentration(MIC). 
Drug Susceptible  
 
Intermediate  
 
Resistant. 
 
Vancomycin ≤ 2μg/ml  4-8μg/ml  ≥16μg/ml 
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Meropenem 
 
≤ 2μg/ml 4μg/ml ≥ 8 μg/ml 
 
Statistical analysis: 
SPSS for windows Version SPSS 20 is used for data entry analysis. All P values 
<0.05 were considered to be significant statistically. 
 
 
RESULTS: 
This study was conducted in the MICU setting of Government General Hospital. 
Chennai from October 2014 to August 2015. 
A total of 100 patients who full filled the inclusion criteria were taken into the 
study.  
 
Table1:Ageand Gender distribution of suspected VAP patients.(n=100). 
 
Age Group Male Female Total Percentage 
< 30 13 12 25 25% 
31-40 7 5 12 12% 
41 – 50 12 7 19 19% 
51 -60 18 4 22 22% 
40 
 
61-70 9 4 13 13% 
>70 8 1 9 9% 
Total 67 33 100 100% 
 
 
 
Among the suspected VAP patients,majority(25%) of patients belong to less than 30 
years and 22% belongs to 51-60 years. 
Gender Distribution of suspected VAP Patients.(N=100) 
25%
12%
19%
22%
13%
9%
0%
5%
10%
15%
20%
25%
30%
< 30 31-40 41 - 50 51 -60 61-70 >70
Age distribution of  suspected VAP 
patients.(N=100)
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Out of the 100 patients included in the study,67 (67%) were males &33(33%) were 
females.  
 
Table-2 Clinical Spectrum of Patients included in the study(N=100) 
 
Diagnosis Total N=100 Percentage 
Poisoning 33 33% 
Cardiovascular Diseases 17 17% 
Intra-abdominal diseases 13 13% 
Neurological Disorders 11 11% 
Sepsis 10 10% 
CNS Infections 9 9% 
Head injury 5 5% 
Neurotoxic Snakebite 2 2% 
 
67%
33%
Gender Distribution -suspected VAP patients  
Male
Female
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The clinical spectrum of patients included in the study was shown in Table-2.It 
indicates that the maximum number of cases enrolled in the study were of poisoning 
(33cases) followed by Cardiovascular diseases (17),Intra abdominal 
diseases(13),Neurological disorders(11),Sepsis (10),CNS infections (9),head 
injury(5),Neurotoxic snake bite(2)  
 
 
 
 
 
 
Clinical Spectrum of Patients included in the study:(N=100) 
 
 Table 3 Distribution of samples among the patients(N=100) 
S.no Samples Count 
33
17
13
11
10
9
5
2
0 5 10 15 20 25 30 35
Poisoning
Cardiovascular Disease
Intra abdominal diseases
Neurological Disorders
Sepsis
CNS Infections
Head injury
Neurotoxic Snakebite
Clinical Spectrum of suspected VAP Patients 
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1 
Respiratory Sample  
                       a.       Endotracheal aspirates(ETA)  
 
100 
                       b.       BAL(Broncheoalveolar lavage)  11 
2 Blood  100 
 
Both endotracheal aspirates and Bronchioalveolar lavage specimen were collected 
from 11 patients out of 100 patients.   
 
 
 
 
Table 4 Correlation between pus cells in Gram stain and growth in 
quantitative culture: 
 
Gram Stain 
 
                Quantitative Culture of ETA Total 
≥ 105 Cfu/ml 
(Pathogens) 
N=23 
<105Cfu/ml 
(colonizers) 
N=44 
NG 
N=33 
No. of pus 
cells/HPF 
>10 19 83% 6 14% 0 29 
1-10 4 17% 31 70% 9 40 
  0 - - 7 16% 24 31 
Respiratory Samples. Quantitative culture. 
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Table 5 Results of Quantitative culture of respiratory samples. 
 
Same pathogens were isolated from both endotracheal aspirates and          
bronchioalveolar lavage in 3 patients. 
 
Correlation of Gram stain findings with quantitative culture. 
Gram stain Findings Quantitative culture 
Pathogens Colonizers NG 
Pus cells +,organism+ 19(83%) 2 4.5% 0 
Pus cells +,organism - 4(17%) 39 88.5% 5(15%) 
Pus cells - ,organism + 0 3 7% 0 
Pus cells  -,organism - 0 0 0 28(85%) 
 
The presence of  >10 pus cells /HPF with ≥1 bacteria per oil immersion field is an 
useful method for presumptive diagnosis of VAP. 
Table7 Clinical Pulmonary Infection Score (CPIS Score) 
Threshold of 
Pathogens 
Threshold of 
Colonizers 
ETA 
≥ 105 
Cfu/ml 
BAL 
≥ 104 
Cfu/ml 
ETA 
<105 
Cfu/ml 
BAL 
<104 
Cfu/ml 
Endotracheal aspirates (ETA).N=100 
23 NA 37 NA 
Broncheoalveolarlavage(BAL).N=11 
NA 3 NA 7 
Total 23 44 
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CPIS Score No of Patients 
≤6 77 
>6 23 
 
The patients with CPIS score of  >6 were diagnosed as VAP patients. 
The mean CPIS of confirmed VAP cases(8.48±1.238)  were significantly higher 
than that of  No VAP group (3.55±0.804)(The two tailed p value is <0.0001). 
 
 
 
 
Table 8 Calculation of VAP rate per 1000 ventilator days: 
Month No of Patients 
on Mechanical 
Ventilation. 
Duration of  
mechanical 
ventilation 
(In days) 
No. of  VAP 
cases 
diagnosed. 
VAP Rate per 
1000 ventilator 
days. 
77%
23%
CPIS score
<6 >6
46 
 
December 2014 118 263 4 15 
January 2015 109 206 3 14.5 
February 2015 91 212 4 18.8 
March 2015 104 209 3 14.4 
April 2015 120 301 5 16.6 
May 2015 112 242 4 16.5 
Total 654 1433 23 16(average) 
In this study ,the VAP rate was  16 per 1000 ventilator days 
 
Table9 Age and Gender distribution of  confirmed VAP patients.(N=23) 
Age Group 
Male 
N=17 
Female 
N=6 
Total 
N=23 Percentage 
< 30 1 3 4 17% 
31-40 2 0 2 9% 
41 – 50 2 2 4 17% 
51 -60 7 0 7 31% 
61-70 3 1 4 17% 
>70 2 0 2 9% 
 
The age  and gender distribution of  confirmed VAP cases were studied and it was 
found that,the incidence of VAP was highest in patients of age between 51-60 years 
. Males(74%) were commonly affected than females(26%). 
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Table10 Clinical Spectrum of confirmed VAP patients.N=23 
Diagnosis Total N=23 Percentage 
 OPC Poisoning 7 30% 
Cardiovascular Diseases 3 13% 
Intra-abdominal diseases 4 17% 
Neurological Disorders 2 9% 
Sepsis 3 13% 
CNS Infections 1 4% 
Head injury 3 13% 
 
The highest percentage of VAP occurrence was seen among patients with Organo 
phosphorus poisoning (30%) followed by intra abdominal diseases 
(17%),Sepsis(13%),head injury(13%). 
74%
26%
Gender distribution  confirmed VAP Patients 
Male
Female
  
Table 11.VAP onset. 
 
NS-Not Significant. 
 
 
VAP onset. 
Out of 23 confirmed VAP patients, 8(35%) were 
& 15(65%) were categorised under late onset VAP.
Table 12 Risk factors in patients included in the study:
VAP Onset Number of Patients (N
Early 8 
Late 15 
categorised under early onset VAP 
 
((N=100)
Early Onset 
34.8%
Late Onset 
65.2%
Onset of VAP
-23) Percentage 
34.8% 
65.2% 
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P value 
0.144 
NS 
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Risk factors Total VAP Percentage Pvalue 
Prior antibiotics 26 16 61.5% 0.023(S) 
Tracheostomy 19 8 42% NS 
Stress ulcer prophylaxis 37 7 19% NS 
Impaired consciousness 17 6 35% NS 
IV sedation 12 6 50% NS 
Reintubation 7 5 71% 0.025(S)  
Nasogastric tube 17 4 24% NS 
Emergency intubation 5 3 60% 0.045(S)  
S-Significant,NS-Not significant. 
 
 
VAP Pathogens: 
0
5
10
15
20
25
30
35
40
Risk factors 
VAP
Total
50 
 
The majority of the bacterial isolates were found to be gram negative 
bacilli(91%),of which Non fermentors(65%) were the predominant pathogens 
isolated from confirmed VAP patients  in our study.The gram positive organism 
accounts for 9% of the  VAP isolates ,of which all were methicillin resistant 
staphylococcus aureus. Of the 23 patients diagnosed as VAP pathogens,21 (91%) 
patients had monomicrobial infection and 2 (9%) patients had polymicrobial 
infection. 
 
 
 
Table 13 VAP Pathogens(N=23) 
 
Sr.no VAP Pathogens(N=23) Count. (N=23) Percentage 
1 Gram negative bacilli 21 91% 
2 Gram positive cocci 2 9% 
 
 
 
 
  
 
 
 
 
 
 
Table-14 - Etiological Agents of VAP(n=23)
Organism 
Acinetobacterbaumannii
Pseudomonas aeruginosa
KlebsiellaPneumoniae
KlebsiellaOxytoca 
 
Total n=23 Percentage
 9 39%
 6 26%
 3 13%
2 9%
GNB
91%
GPC
9%
VAP Pathogens
51 
 
 
 
 
 
 
GNB GPC
52 
 
E.Coli 1 4% 
Staphylococcus aureus 2 9% 
 
The most frequently isolated organisms in VAP patients were 
Acinetobacterbaumannii (39%) followed by Pseudomonas aeruginosa 
(26%),Klebsiellapneumoniae (13%),Klebsiellaoxytoca(9%),E.coli(4%), 
Staphylococcus aureus(9%). 
 
 
 
 
 
 
 
 
 
Table 15 – Distribution of pathogens among early and late onset VAP   
Organism Early (n=8) 
 
percentage 
Late 
(n=15) Percentage 
Acinetobacterbaumannii 1 12.5% 8 53% 
Pseudomonas aeruginosa 2 25% 4 27% 
KlebsiellaPneumoniae 2 25% 1 7% 
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KlebsiellaOxytoca 2 25% 0 - 
E.Coli 1 12.5% 0 - 
Staphylococcus aureus 0 - 2 13% 
 
 
 
 
The predominant organism in the late onset VAP was 
Acinetobacterbaumannii(53%) followed by Pseudomonas aeruginosa(27%).The 
predominant organism in the early onset VAP group were  Pseudomonas 
aeruginosa(25%),Klebsiella pneumonia(25%) and klebsiellaoxytoca(25%). 
 
Table:16 Distribution of respiratory tract Colonizers in mechanically 
ventilated patients.(N=100) 
1
2 2 2
1
8
4
1
2
0
1
2
3
4
5
6
7
8
9
10
Acinetobacter 
baumannii
Pseudomonas 
aeruginosa
Klebsiella 
Pneumoniae
Klebsiella 
Oxytoca
E.Coli Staphylococcus 
aureus
Distribution of pathogens among early and late onset VAP
Early Late
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Sno Organism(Colonizer) Count Percentage 
1 Acinetobacterbaumannii 10 23% 
2 Acinetobacterlwoffii 3 7% 
3 KlebsiellaPneumoniae 10 23% 
4 KlebsiellaOxytoca 2 4.5% 
5 Pseudomonas aeruginosa 8 18% 
6 Pseudomonas fluorescens 1 2% 
7 Staphylococcus aureus 4 9% 
8 Staphylococcus epidermidis 2 4.5% 
9 Escherichia coli 2 4.5% 
10 Candida albicans 2 4.5% 
 Total 44 23% 
 
 
 
The common organisms colonizing the respiratory tract were 
Acinetobacterspecies(30%),klebsiella species(27.5%) and pseudomonas species 
(20%).Staphylococcus aureus (9%) was the common gram positive colonizer . 
Staphylococcus epidermidis, Escherichia coli and Candida albicans were the other 
relatively less common colonizers. 
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Table 17: Distribution of etiological agents causing bacteremiaamong  
confirmed VAP Patients (n=23) 
S.no Blood Culture VAP % P value 
1 Acinetobacterbaumannii 1 4.3  
 
0.721 
Not 
2 KlebsiellaPneumoniae 1 4.3 
3 KlebsiellaOxytoca 1 4.3 
4 Pseudomonas aeruginosa 2 9 
0 5 10 15
Acinetobacter baumannii
Acinetobacter lwoffii
Klebsiella Pneumoniae
Klebsiella Oxytoca
Pseudomonas aeruginosa
Pseudomonas fluorescens
Staphylococcus aureus(MSSA)
Staphylococcus epidermidis
Escherichia coli
Candida albicans
Colonizers of mechanically ventilated patients  
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5 Staphylococcus aureus 3 13.1 Significant 
 Total 8 35 
 
 
Blood culture:  
Out of 23 VAP cases, blood culture was positive in 8 patients.The organisms 
isolated were Acinetobacterbaumannii, KlebsiellaPneumoniae,KlebsiellaOxytoca, 
Pseudomonas aeruginosa, Staphylococcus aureus.The sensitivity of blood cultures 
for the diagnosis of VAP is low and also if positive,the organisms may originate 
from an extrapulmonary site of infection.  
Antimicrobial susceptibility pattern of the Gram negative and Gram positive 
isolates causing VAP is shown below.Most of the Gram negative organisms and 
gram positive organisms isolated were multidrug resistant. 
 
 
 
Table 18: Antimicrobial sensitivity pattern of Gram negative isolates 
Organism 
A
K
 
C
O
T
 
C
IP
 
C
T
X
 
C
A
Z
 
C
A
C
 
C
X
 
G
M
 
IM
P
 
M
E
R
 
P
T
 
Acinetobacterb
aumannii(n=9) 
44
%
  (
4)
 
22
%
  (
2)
 
33
%
 (
3)
 
- 11
%
(1
) 
- 44
%
(4
) 
22
%
 (
2)
 
67
%
 (
6)
 
67
%
 (
6)
 
44
%
 (
4)
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Pseudomonas 
aeruginosa 
(n=6) 
67
%
 (
4)
 
- 17
%
 (
1)
 
- 33
%
 (
2)
 
- 50
%
(3
) 
50
%
 (
3)
 
61
%
 (
4)
 
61
%
 (
4)
 
50
%
 (
3)
 
Klebsiellapneu
moniae (n=3) 
67
%
 (
2)
 
0%
 
33
%
 (
1)
 
0%
 
0%
 
67
%
 (
2)
 
67
%
 (
2)
 
33
%
 (
1)
 
10
0%
 (
3)
 
10
0%
 (
3)
 
67
%
 (
2)
 
Klebsiellaoxyt
oca             
(n=2) 
50
%
 (
1)
 
0%
 
50
%
 (
1)
 
0%
 
0%
 
10
0%
 (
2)
 
10
0%
 (
2)
 
50
%
 (
1)
 
10
0%
 (
2)
 
10
0%
 (
2)
 
10
0%
 (
2)
 
E.Coli  (n=1) 
10
0%
 (
1)
 
0%
 
0%
 
0%
 
0%
 
10
0%
 (
1)
 
10
0%
 (
1)
 
10
0%
 (
1)
 
10
0%
 (
1)
 
10
0%
 (
1)
 
10
0%
 (
1)
 
  
AK-Amikacin,COT-Cotrimoxazole,CIP-ciprofloxacin,CTX-cefotaxime,CAZ-
ceftazidime,CAC-Ceftazidime&clavulanic acid,CX-cefoxitin, 
GM-Gentamicin,IMP-Imipenem,MER-Meropenem, 
PT-Piperacillintazobactum. 
 
The nonfermentors showing resistance to carbapenemswere further subjected to 
Macrobroth dilution method for determining the MIC. 
 
Table 19.Sensitivity to meropenem by Disc diffution method and Macrobroth 
dilution method 
 Number of isolates resistant to Meropenem 
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          Method Acinetobacterbaumannii
. 
Pseudomonas 
aeruginosa 
Count Percentage Count Percentag
e 
Kirby Bauer’s Disc Diffusion 
method. 
3 33% 
(3/9) 
2 33% 
(2/6) 
Macrobroth dilution method 3 33% 2 33% 
  
The isolates of nonfermentors showing resistance to carbapenem (meropenem) by 
Disc Diffusion method also showed resistance by Macrobroth dilution method with 
a MIC value of  >8µg/ml. 
 
 
 
 
 
 
Antimicrobial sensitivitypattern of Acinetobacterbaumannii. 
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Antimicrobial sensitivitypattern of Pseudomonas aeruginosa 
 
67% isolates of Pseudomonas aeruginosa were sensitive to amikacin,67% to 
carbapenems and 50% to Piperazilintazobactum. 
 
 
Antimicrobial sensitivity pattern of Enterobacteriaceae 
44%
22%
33%
11%
44%
22%
67% 67%
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0%
10%
20%
30%
40%
50%
60%
70%
80%
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67%
17%
33%
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50%
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40%
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AK CIP CAZ CX GM IMP MER PT
Pseudomonas aeruginosa
Sensitive
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The isolates of Enterobacteriacea were 67% sensitive to Amikacin83% to 
Piperazilin-tazobactum.All were sensitive to carbapenems. 
Table20 Distribution of Beta-lactamases produced by Gram negative VAP 
pathogens. 
Organism Total ESBL AmpC MBLs 
Acinetobacterbaumannii 9 - 2(22%) 3(33%) 
Pseudomonas aeruginosa 6 - 1(17%) 2(33%) 
KlebsiellaPneumoniae 3 2(67%) 1(33%) - 
KlebsiellaOxytoca 2 2(100%) - - 
E.Coli 1 1(100%) - - 
Total 21 5 4 5 
P value 
 0.007 
Significant 
0.007 
Significant 
0.001 
Significant 
 
67%
0%
33%
0% 0%
83% 83%
50%
100% 100%
83%
0%
20%
40%
60%
80%
100%
120%
AK COTRI CIP CTX CAZ CAC CX GM IMP MER PT
Enterobacteriaceae
Sensitive
  
 
Gram negative isolates among VAP pathogens were tested for the production of 
various beta lactamases, showed ESBL(Extended spectrum beta lactamase) 
production in 83% isolates of Enterobacteriaceae. ESBL was produced by 100% of 
E. coli, 67% of K. pneumoniae
AmpC beta lactamases were produced by 33% of 
22% of  Acinetobacterbaumannii
MBL(Metallobeta lactamases)  were produced by 33% of
and 33% of pseudomonas aeruginosa.
 
 
Acinetobacter 
baumannii
Pseudomonas 
aeruginosa
0 0
22%
17%
33%
Distribution of Beta
Gram negative VAP pathogens.
, 100% of klebsiellaoxytoca. 
klebsiellapneumonia 
,17% of Pseudomonas aeruginosa
Acinetobacterbaumannii
 
Klebsiella 
Pneumoniae
Klebsiella 
Oxytoca
E.Coli
67%
100% 100%
33%
0 0
33%
0 0
-lactamases produced by 
61 
 isolates, 
. 
 
0
ESBL
AmpC
MBLs
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Table 21:Antimicrobial sensitivity pattern of Staphylococcus aureus. 
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MRSA (2) 
S S S S S S S S S 
0% 0% 
50% 
(1) 
0% 
50% 
(1) 
0% 0% 50% (1) 50% (1) 
 
MRSA(Methicillin resistant Staphylococcus aureus) isolates were tested for 
Vancomycin MIC using Macro broth dilution method and E (Epsilometer)  test 
method. 
Table 22.Minimum Inhibitory Concentration of Vancomycin for MRSA 
isolates. 
MRSA isolate Vancomycin MIC Valuein µg/ml Interpretation 
Macrobroth dilution method E test method 
1 0.50 0.75 Sensitive 
2 0.25 0.25 Sensitive 
 
Both the MRSA isolates were sensitive to Vancomycin with an MIC value of less 
than 2µg/ml. 
 
 Table 23 Correlation of duration of mechanical ventilation,Onset of VAP with 
multi drug resistant organisms.
Duration of 
mechanical 
ventilation 
 ≤ 4days 
 ≥ 5days 
 
 
.
Out of 23 VAP pathogens ,16 were multidrug resistant pathogens.
 
 
 
 
Total VAP pathogens Vs MDR Pathogens
 
Onset of 
VAP 
Total VAP 
pathogens. 
N=23. 
MDR 
pathogens 
N=16. 
percentage
Early 8 5 63%
Late 15 11 73%
Total VAP 
pathogens, 23
MDR 
pathogens, 16
63 
 P value 
 0.134 
NS  
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Distribution of MDR pathogens among VAP pathogens.(N=16) 
 
 
Table24 Clinical Outcome among patients with Suspected VAP.(N=100). 
Clinical Outcome Suspected VAP Patients(n=100) Total P value 
Confirmed 
VAP(n=23) 
No VAP 
(n=77) 
Died 8(35%) 11(14%) 19 0.028 
Significant Discharged 15(65%) 66(86%) 81 
 
The outcome of VAP was considered in terms of death and discharge. 
Out of 23 confirmed VAP patients ,8(35%) patients died.Hence mortality rate is 
35% among the VAP patients. 
 
1
2
1
2
1
2 2
3
2
MDR Pathogens N=16
 Table 25 Clinical Outcome in confirmed VAP patients with respect to VAP 
onset.(n=23) 
                        Outcome
Onset 
Early  (8) 
Late (15) 
 
Themortality in late onset VAP was significantly high at 46.5% with the death of 7 
patients out of 15 during the course of their illness.However
low at 12.5%in early onset VAP with the death of 1 patient out of 8 during the 
course of their illness. It was observed
onset VAP. 
 
 
Death 
Outcome in Confirmed VAP patients 
 
Death Discharged
1(12.5%) 7(87.5%)
7(46.5%) 8(53.5%)
 mortality was relatively 
 that more number of deaths occured
Death-12.50%
-46.50%
based on VAP onset
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 in late 
Early
late
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Table26Correlation of mortality and infectious agents among VAP 
patients(N=23) 
Sr.no. Organism  VAP Death 
N=8 
Percentage No.MDR 
Pathogen 
Percentage 
Of MDR 
Pathogen 
1 Acinetobacterbau
mannii 
5 62.5% 
(5/8) 
4 80% 
(4/5) 
2 Pseudomonas 
aeruginosa. 
2 25% 
(2/8) 
1 50% 
(1/2) 
3 Klebsiellapneumo
niae 
1 12.5% 
(1/8) 
1 100% 
(1/1) 
 
The majority(62.5%) of patients died among confirmed VAP cases were due to 
Acinetobactorbaumannii infection .The next most lethal organism was 
pseudomonas aeruginosa with a mortality rate of 25% followed by 
klebsiellapneumoniae 12.5%. 
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Correlation of mortality and infectious agents: 
 
 
 
The majority(62.5%) of patients died among confirmed VAP cases were due to 
Acinetobactorbaumannii infection. 
 
 
 
 
 
 
 
 
Death
62.50%
Death
25%
Death
12.50%
Correlation of mortality and infectious agents
Acinetobacter baumannii Pseudomonas aeruginosa Klebsiella pneumoniae
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DISCUSSION 
This cross sectional study was done at the Institute of Microbiology, in association 
with the Institute of Internal Medicine, at the Rajiv Gandhi Government General 
Hospital, Chennai . 
 
A total of 100 patients with suspected Ventilator associated pneumonia who 
satisfied the inclusion criteria were included in this study of which 67 were males 
and 33 were females with majority of the patients belong to the age group of  less 
than 30yrs(25%) followed by 51-60yrs.(22%) [Table 1] 
 
 The clinical spectrum of study population indicates that the maximum number of 
cases enrolled in the study were of poisoning (33%) followed by Cardiovascular 
diseases(17%) [Table 2] 
 
The American Thoracic Society guidelines suggests that Endotracheal aspirates and 
Bronchioalveolar lavage can provide more representative samples than the 
Protected specimen brush (PSB) which sample only a single bronchial segment.(2) 
 
The samples obtained from the study population were Endotracheal 
aspirates,Bronchioalveolar lavage  and Blood.[Table 3] 
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Pugin et al proposed Clinical Pulmonary Infection Score(CPIS) to improve the 
specificity of clinical diagnosis based on clinical,radiological,physiological and 
microbiological data in to a single numerical result.CPIS score of more than 6 was 
associated with a sensitivity of 93% and a specificity of 100% for the diagnosis of 
pneumonia.(31,37)In this study,23% of patients had CPIS score more than 6. 
The American Thoracic Society guidelines states that a reliable tracheal aspirate 
Gram stain can be used to direct initial empiric antimicrobial therapy and may 
increase the diagnostic value of the CPIS.(2). 
In this study,83% of patients with a significant quantitative culture(≥105cfu/ml for 
ETA) had pus cells of more than 10/HPF with one or more bacteria per oil 
immersion field but none of the patients with a negative direct smear had a 
significant quantitative culture.[Table4,6] 
Hence the presence of  >10 pus cells /HPF with ≥1 bacteria per oil immersion field 
is an useful method for diagnosing VAP presumptively. 
Those patients with CPIS more than 6 and quantitative culture of the Endotracheal 
aspirates ≥105cfu/ml and Bronchioalveolar lavage ≥104cfu/ml were confirmed with 
the diagnosis of  VAP.[Table 5]  
Based  on this, 23% of patients in this study were confirmed with  the diagnosis of 
VAP.[Table 7] 
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Various studies have reported the frequency of VAP ranging from 18% by Joseph et 
al  to 57.14 % by Ranjan et al as shown below. 
Frequency of VAP (comparison with other studies) 
 
STUDY YEAR VAP Rates in percentage(%) 
Agrawal et al (25) 2006 23 
Joseph et al (18) 2009 18 
Mukhopadhyay et al (27) 2010 42 
Reena et al (28) 2011 27.22 
Ranjan et al(70) 2014 57.14 
Current study 2015 23 
 
In this study,device associated incidence rate  is 16 per 1000 ventilator  days [Table 
8] which is similar to the study by joseph et al from pondicherry where the 
incidence is 15.87per 1000 ventilator  days in CCU(Critical Care Unit) and 
30.67per 1000 ventilator  days in MICU.Ranjan et al(70) from Madhya Pradesh 
reported the incidence of VAP as 31.7 per 1000 ventilator days whereas Singh et 
al(74) from Gujarat reported the incidence  as 21.92 per 1000 ventilator days 
 
 
The rates of VAP in surgical ICU were higher than in medical ICU’s,depending on 
the difference in patient population,the proportion of patients that needed 
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mechanical ventilation  and the duration of ventilation.The device associated 
incidence rate varies from 13.2-51 per 1000 ventilator days(12).  
In this study VAP was most seen in age group of 51- 60 years[Table 9].It is 
correlating with a study by Dey et al(16), in that the most common age group to 
acquire VAP was between 46-60 years.The mean age for developing VAP was 45 
years in study by Mukhopadhyay et al(27).In this study the mean age for developing 
VAP was 50 years. 
Of the 23 patients who developed VAP in this study 74% were male and 26% were 
female which is similar to a study conducted by EleniApostolopoulou et al(12)  
71% were male and 29% were female and also a study conducted in India by Joseph 
et al(18) reported that 66.7 % were male and 33.3 % were female. 
In the present study,VAP was common among patients with 
Organophophorouspoisoning(30%)[Table10]. Similar study by Panwar et al(67) 
showed VAP associated predominantly with poisoning cases.Poisoning cases are 
subjected to gastric lavage prior to admission.These patients develop severe 
respiratory disease and therefore an  increased need for mechanical ventilation.The 
pulmonary symptoms might be due to aspiration as a result of induced vomiting and 
lavage. Other conditions which required prolonged admission and mechanical 
ventilation like head injury,sepsis  and intra abdominal diseases  also developed  
VAP, which is in concurrence with other studies by Niederman et al(3) and 
Apostopoulou et al(12). 
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Out of the 23 cases of VAP, 34.8% were categorised as early-onset  and 65.2% 
were late-onset VAP[Table 11]. Similar results were obtained by Mukhopadhyay et 
al(27)  with38% being early-onset VAP and 62% late-onset VAP.The categorization 
of VAPis important for starting initial empiric antibiotic therapy.The late onset 
VAP is commonly associated with MDR pathogens,hence should be treated with 
broad spectrum antibiotics.(2) 
In the current study,among the various risk factorsanalysed,reintubation(71%)(P 
value 0.025),Prior antibiotics(61.5%)(P value 0.023), and emergency 
intubation(60%) (P value 0.045),were significantly associated with VAP[Table 
12].Similarly Agrawal et al(25) had reported an increased risk of VAP in patients 
who underwent re-intubation.Awarenessof these risk factors may help in identifying 
patients at increased risk for VAP and guide inimplementation of appropriate 
preventive measures during management. 
In this study,it was observed that,hospitalization of 5 days or more is associated 
with the development of VAP with MDR pathogens like Acinetobacterbaumanni 
and Pseudomonas aeruginosa which is similar to a study by Ranjan et al(70). 
In the present study, Gram negative bacilli were the predominant pathogens(91%) 
followed by Gram positive cocci(8%)[Table 13] similar to a study by Rajesh chawla 
et al(6) who reported that  87% of patients with VAP were infected with Gram 
negative bacilli.Among the Gram negative bacilli,non fermenters were the  
predominant pathogens  causing VAP in our IMCU. 
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In the present study,Acinetobacterbaumannii(39%) followed by pseudomonas 
aeruginosa(26%) was found to be the most commonly isolated pathogens in VAP 
patients and also they are associated with late onset VAP ,similar to a study by 
craven et al(13).The common organism causing early onset VAP were from the 
group of Enterobacteriaceae like Klebsiella 
pneumonia(25%),Klebsiellaoxytoca(25%)and E.coli(12.5%).[Table 14,15]In a study 
by Dey et al (16) from Manipal,the commonest organismcausing both early and late 
onset VAPwasAcinetobacter species  (48.94%) followed by P.aeruginosa 
(25.53%). 
Hence,the knowledge of  difference in microorganisms causing VAP in different 
ICU settings will guide the prescription of appropriate empirical antibiotics and  
treatment of the infection adequately. 
Acinetobacterspecies(30%),klebsiella pneumonia(23%) and pseudomonas 
aeruginosa (18%)were the common organisms colonizing the respiratory tract of 
the patients on mechanical ventilation in this study[Table 16].The knowledge about 
the colonizers is important as reported by Alp et al (31)that the aspiration of 
colonizers  on the oropharynx and those on the gastrointestinal tract is the main 
route for the development of Ventilator Associated Pneumonia. 
Acinetobacter species are particularly important in causing nosocomial outbreaks 
and readily spread from one patient to another. This appears to be due to their 
ability to survive on the hands of health care workers and inanimate environmental 
surfaces and their intrinsic resistance to many common antibiotics rather than any 
potent virulence factors aimed at host defenses.  
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In thisstudy,out of 23 VAP patientsblood culture was positive in 8(35%) 
patients.Among the 8 patients,identical pathogens were isolated from both blood 
culture and respiratory sample in 5 patients(22%).[Table17] which is similar to a 
study byLuna et al(73)Antimicrobial susceptibility pattern of the isolates obtained 
in the present study showed that 70% of these  VAP pathogens were  resistant to 
commonly used drugs which is similar to a study conducted by Joseph et al(9) 
where 78.7% of VAP pathogens were multi drug resistant. 
Acinetobacterbaumannii,the predominant pathogen isolated in this study showed  
decreased susceptibility to first line drugs like Ceftazidime(11%), 
quinolones(ciprofloxacin)(33%), and Amikacin(44%).They were 67% sensitive to 
carbapenems and 44% sensitive to Piperacillintazobactum.[Table18] 
In Pseudomonas aeruginosa,67% isolates were sensitive to amikacin,67% to 
carbapenems,50% to Piperazilintazobactum.Similar results were obtained in studies 
conducted by Joseph et al(9) and Dey et al(16). 
All the Nonfermentors showing resistance to carbapenems by Kirby Bauer disc 
diffusion method were further tested for MIC of meropenem by macrobroth dilution 
method.There was a good agreement between Kirby Bauer disc diffusion method 
and MIC in determining the susceptibility of non fermenters to meropenem in our 
study[Table 19],though Sinha et al(72) had reported discordant results between 
Kirby Bauer disc diffusion method and MIC determination by broth microdilution 
method with 18 out of 21 isolates resistant by disc diffusion method being sensitive 
to micro broth dilution method.  
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The isolates of Enterobacteriaceae were 67% sensitive to Amikacin ,33% sensitive 
to quinolones and 83% sensitive to Piperazilin-tazobactum.All isolates were 
sensitive to carbapenems. 
The members ofEnterobacteriaceaeisolated in this study showed a high level of 
resistance(100%)to Extended spectrum cephalosporins. Emergence of Extended 
spectrum beta lactamases (ESBLs) and AmpCbetalactamasesin a hospital set up are 
of increasing concern. 
In this study, ESBLproduction was observed in  67% of  K.pneumoniae,100% of 
Escherichia coli and 100% of Klebsiellaoxytoca.[Table 20]In a study by Dey et 
al(16),100% of K.pneumoniae and 80% of  Escherichia coli produced ESBLs. 
Although there is nocurrent(Clinical Laboratory Standards institute) CLSI 
guidelines for detection of AmpC beta lactamases, the present study incorporated 
the AmpC-disc method suggested by Singhal et al(65) to detect AmpC beta 
lactamases.17% of Pseudomonas aeruginosa,22% of Acinetobacterbaumannii,and 
33% of Klebsiellapneumoniae,  have shown production of AmpC beta lactamases in 
our study ,similar to a study by Dey et al(16). 
In this study ,33% of Acinetobacterbaumannii and 33% of Pseudomonas 
aeruginosa were metallobetalactamase enzyme producing strains detected by 
imipenem EDTA combined disc method[Table 20] whereas Hans et al(75) from 
U.P  reported MBL production by 47.05% of Acinetobacterbaumannii. Dey et al 
(16) from Manipal reported MBL production in 21.74% of Acinetobacterbaumannii 
and 50% of Pseudomonas aeruginosa. 
76 
 
 
In this study 2 isolates of Staphylococcus aureus were isolated,of which both were 
Methicillin resistantStaphylococcusaureus and is associated with late-onset 
VAP.These isolates showed 50%sensitivity to quinolones and  to Amikacin[Table 
21]. 
All isolates were  sensitive to Vancomycin which was detected by Macrobroth 
dilution method and E test method[Table 22].Whereas otherstudies have 
shownthatStaphylococcusaureus (methicillin sensitive or resistant) to be a major 
causative agent of early-onset VAP(3,69) which is different  from the present 
study.This indicates that the causative agents may vary in different ICUsettings. 
In the present study, it was found that the mortality rate among the VAP patients 
was 35%[Table 24]. Similar findings were reported in studies undertaken by 
Panwar et al(67) and Mukhopadhyay et al(27) where mortality rates were found to 
be 37% and 61.9% respectively. 
In this study ,it was seen that the mortality was significantly high in patients with 
late-onset VAP(46.5%)[Table 25] caused by multidrug resistant 
Acinetobacterbaumanniiand Pseudomonas aeruginosa infection when compared to 
early onset VAP(12.5%).[Table 26]. 
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SUMMARY 
 This cross-sectional study was done by enrolling patients admitted to MICU 
and receiving mechanical ventilation for ≥48 hours with clinical and radiological 
parameters indicative of VAP 
 A total of 100 patients with suspected Ventilator associated pneumonia who 
satisfied the inclusion criteria were included in this study of which 67 were males 
and 33 were females with majority of the patients belong to the age group of  less 
than 30yrs(25%) followed by 51-60yrs.(22%) . 
 The clinical spectrum of patients included in the study were poisoning (33%) 
followed by Cardiovascular diseases (17%) and Intraabdominal diseases (13%). 
 Endotracheal aspirates /BAL and blood  samples were collected from  
suspected VAP patients and quantitative cultures were done on respiratory  samples. 
 The presence of  >10  pus cells /HPF with ≥1 bacteria per oil immersion field 
is an useful method for presumptive diagnosis of VAP. 
 VAP was diagnosed using the CPIS score > 6 and quantitative culture of  
≥105CFU/ml for endotracheal aspirates  and ≥104CFU/ml for BAL samples. 
 Out of 100 suspected VAP patients,23 were confirmed with the diagnosis of 
VAP. 
 The VAP rate in our study was 16 per 1000 ventilator days. 
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 Ventilator associated pneumonia was  preponderant in males, the common 
age group being 51- 60 years. 
 VAP was common among patients with Organophophorouspoisoning(30%). 
 Among the 23 confirmed VAP patients, 34.8% had early-onset  VAP and 
65.2% had late-onset VAP. 
 Among the risk factorsanalysed,reintubation(71%),Prior antibiotics(61.5%) 
and emergency intubation(60%) were predominantly associated with VAP. 
Hospitalization of 5 days or more is associated with the development of VAP with 
Multi drug resistant pathogens. 
  Among the 23 VAP pathogens,91% were Gram negative bacilli and 9% 
were Gram positive cocci. 
 Non fermenters(65%) were the  predominant pathogens among Gram 
negative bacilli causing VAP in our IMCU. 
 Acinetobacterbaumannii (39%)  followed by P.aeruginosa (26%)  were the 
commonly isolated pathogens in VAP patients which were associated with late 
onset VAP. 
 The common organisms causing early onset VAP were from the group of 
Enterobacteriaceae like Klebsiellapneumonia(25%) and Klebsiellaoxytoca(25%). 
 Out of  23  VAP patients, blood culture was positive in 35% patients of 
which 22% patients showed positive growth in blood culture with the same 
organism isolated from respiratory sample. 
 Antimicrobial susceptibility pattern of the VAP isolates revealed that 70% of 
the pathogens to be multi-drug resistant.  
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 Acinetobacterbaumannii showed decreasedsusceptibility to first line drugs 
like Ceftazidime(11%), quinolones(ciprofloxacin)(33%), and Amikacin(44%).They 
were 67% sensitive to carbapenems and 44% sensitive to Piperacillintazobactum. 
 In Pseudomonas aeruginosa,67% isolates were sensitive to amikacin,61% to 
carbapenems,50% to Piperazilintazobactum. 
 The isolates of Enterobacteriaceae were 67% sensitive to Amikacin ,33% 
sensitive to quinolones  and 83% sensitive toPiperazilin-tazobactum.All  isolates of 
Enterobacteriaceae were sensitive to carbapenems.   
 Staphylococcus aureus isolated in our study showed 50% sensitivity to 
quinolones and to Amikacin.All isolates were sensitive to Vancomycin ,detected by 
Macrobroth dilution method and E test method.Both the isolates were methicillin 
resistant Staphylococcus aureus and were associated with late onset VAP. 
 67% of K. pneumoniae , 100% of  K.oxytoca and  E. coli produced extended 
spectrum beta lactamases (ESBLs). Metallo β-lactamases (MBLs) production was 
seen in 33% of Pseudomonas aeruginosa  and 33% of 
Acinetobacterbaumannii.AmpC beta lactamase production was seen in 33%  
ofklebsiella pneumonia,22% of Acinetobacterbaumannii and 17% of pseudomonas 
aeruginosa. 
 The mortality rate in ventilator associated pneumonia was 35 % in this study. 
The rate was higher in patients with multidrug resistant organisms like 
Acinetobacterbaumannii  andPseudomonas aeruginosa infection. 
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CONCLUSIONS: 
 Ventilator associated pneumonia is preponderant in males, the common age group 
being 51- 60 years. 
 VAP was common among patients with Organophophorous poisoning. 
 Direct gram stain was found to be useful predictor of VAP. 
 The significant risk factors associated with the development of VAP were re-
intubation,prior antibiotics and emergency intubation. 
 Gram negative bacilli are the significant contributor to the development of 
VAP,among which nonfermentors like Acinetobacterbaumannii followed by 
pseudomonas aeruginosawere the commonest pathogens isolated.  
 The causative organisms for early onset VAP is different from late onset 
VAP.Increase in association of  MDR pathogens with late onset VAP indicates that 
appropriate broad spectrum antibiotics should be prescribed. 
 MDR pathogens increase mortality in VAP patients due to the production of 
ESBLs,AmpCbetalactamases and metallobetalactamases. 
 Thus this study gives a knowledge on the baseline VAP rate,risk factors, the causative 
organism and the prevailing drug susceptibility pattern of our Medical Intensive Care 
Unit,which will benefit in improving the active surveillance programme aimed towards 
an effective hospital infection control strategy.   
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                                                          APPENDIX I 
 
ABBREVIATIONS 
VAP           -Ventilator-associated pneumonia. 
HAP           -Hospital Acquired Pneumonia. 
ICU            -Intensive Care Unit. 
MICU         -Medical Intensive Care Unit. 
MV             -Mechanical Ventilation. 
MDR          -Multi Drug Resistant. 
ETA           -Endotracheal Aspirate. 
BAL           -Bronchioalveolar Lavage. 
PSB            -Protected Specimen Brush. 
ESBL         -Extended Spectrum Beta lactamases. 
MBL          -Metallobeta lactamases. 
MRSA        -Methicillin resistant Staphylococcus aureus. 
MSSA        -Methicillin sensitive Staphylococcus aureus. 
  MIC         -Minimum Inhibitory Concentration 
CLSI           -Clinical Laboratory Standards Institute. 
ATCC         -American Type Culture Collection. 
IHI              –Institute  of  Healthcare  Improvement
  APPENDIX II 
 
A. STAINS AND REAGENTS 
 
1. Gram staining 
 
Methyl violet (2%)    l0g Methyl violet in 100ml absolute 
      alcohol in 1 litre of distilled water  
      (primary stain)  
Grams Iodine    l0g Iodine in 20g KI (fixative) 
Acetone     Decolourising agent  
Carbol fuchsin 1%    Secondary stain.  
 
2.10%KOH 
 
Potassium hydroxide           10g 
Glycerol                            10ml 
Distilled water                       80ml 
 
3.Lacto Phenol Cotton blue stain 
Lactic acid                          20ml 
Phenol                                20ml 
Cotton blue(dye)                0.5g 
Glycerol                                  40ml 
Distilled water                        20ml 
 
B. MEDIA USED:   
 
1. Mac Conkey agar  
 
Peptone                            20g   
Sodium taurocholate          5g    
Distilled Water                     1ltr   
Agar                                20g    
2% neutral red in 50%  
ethanol       3.5ml   
10% lactose solution             100ml   
 
 
 
Dissolve peptone and taurocholate in water by heating. Add agar and dissolve            
it in steamer. Adjust pH to 7.5. Add lactose and neutral red shake well and mix. 
Heat in free steam (100°C) for 1 hour, then autoclave at 115°C for 15 minutes. 
 
 
 
 
3. Blood agar (5% sheep blood agar) 
 
Peptone l0g 
 
NaCl 5g 
 
Distilled water 1 Ltr 
 
Agar l0g 
 
Dissolve  ingredients  in  distilled  water  by  boiling,  and  add  5%  sheep 
 
blood(sterile) at 55°C adjust pH to 7.4. 
 
 
4. Chocolate agar 
 
Sterile defibrinated blood 10 ml 
 
Nutrient Agar (melted) 100 ml 
 
 
When the temperature was about 75°C, sterile blood was added with constant 
agitation. After addition of blood, kept in water bath and heating was continued till 
the blood changed to chocolate colour. Cooled to about 50° C and poured about 
15ml into petri dishes with sterile precaution. 
 
5. Cation adjusted Mueller- Hinton Agar 
 
 
Beef infusion 300ml 
Caesein hydrolysate 17.5g 
Starch 1.5g 
Agar l0g 
Distilled water 7 Lltr 
pH = 7.4  
Sterilise by autoclaving at 121°C for 20 mins 
 
 
 
 
 
C. MEDIA REQUIRED FOR BIOCHEMICAL IDENTIFICATION 
 
 
1. Oxidase Reagent 
 
 
Tetra methyl p-phenylene diamine dihyrochloride- 1% aqueous solution. 
 
 
2. Catalase 
 
 
3% hydrogen peroxide 
 
 
3. Indole test 
 
 
Kovac's reagent 
 
 
Amyl or isoamyl alcohol 150ml Para dimethyl amino benzaldehyde lOg 
Concentrated hydrochloric acid 50ml 
 
Dissolve the aldehyde in the alcohol and slowly add the acid. Prepare in small 
quantities and store in the refrigerator. Shake gently before use. 
 
4. Christensen's Urease test medium  
 
Peptone lg 
 
Sodium chloride 5g 
 
Dipotassium hydrogen phosphate 2g 
 
Phenol red 6ml 
 
Agar 20g 
 
Distilled water 1 ltr 
 
 
 
 
10% sterile solution of glucose  10ml 
 Sterile 20% urea solution   100ml 
Sterilize the glucose and urea solutions by filtration. Prepare the basal medium     without 
glucose and urea, adjust to pH 6.8-6.9 and sterilize by autoclaving in a flask at 121°C for 
30min. Cool to about 50°C, add the glucose & urea, and tube the medium as slopes. 
 
 
 
 
 
 
 
Dispense, autoclave at 121°C for 15 min and allow to set as slopes 
 
 
 
 
Heat to dissolve the solids, add the indicator solution, mix and tube. Sterilize   at 
121°C for 15 min and cool to form slopes with deep butts. 
5. Simmon's Citrate Medium  
Koser's medium 1 ltr 
Agar 20 g 
Bromothymol blue 0.2% 40ml 
6. Triple Sugar Iron medium  
Beef extract 3g 
Yeast extract 3g 
Peptone 20g 
Glucose lg 
Lactose 10 g 
Sucrose l0g 
Ferric citrate 0.3g 
Sodium chloride 5g 
S odum thiosulphate 0.3g 
Agar 12g 
Phenol red 0.2% solution 12ml 
Distilled water 1 ltr 
  
Dissolve the peptone and phosphate and adjust the pH to 7.6. Filter dispense 
in 5ml amounts and sterilize at 121°C for 15min.     Sterilize the glucose 
solution by filtration and add 0.25ml to each tube. 
 
To  the  basal  medium  of  peptone  water,  add  sterilised  sugars  of  1%  
indicator bromothymol blue with Durham's tube. Basal medium peptone 
water Sugar solutions: 
 
Sugar 1ml 
 
Dislilled water 100ml 
 
pH = 7.6. 
7. Glucose phosphate broth  
Peptone 5g 
Dipotassium hydrogen phosphate 5g 
Water 1 ltr 
Glucose 10% solution 50ml 
Methyl Red Reagent  
Methyl Red l0mg 
Ethyl alcohol 30ml 
Distilled water 20ml 
Voges Proskauer Reagent  
Reagent A: Alpha naphthol 5g 
Ethyl alcohol 100ml 
Reagent B: Potassium hydroxide 40g 
Distilled water 100ml 
 
 
8. Peptone water fermentation test medium  
 
 
9. Mannitol motility medium  
Agar 5g 
Peptone  lg 
Potassium nitrate 1g 
Mannitol 2g 
Phenol red indicator  
Distilled water 1000ml 
pH 7.2 
 
10. Phenolphthalein diphosphate agar 
 
 
 Sterilize a 1% aqueous solution of sodium phenolphthalein diphosphate by 
filtration and store at 4°C 
 
 Add 10ml of this solution to 1000ml melted nutrient agar cooled to 50°C and pour plates 

 Grow the staphylococcus overnight at 37°C on the medium 

 Invert the plate and pour a few drops of ammonia solution SG 0.88 into the 
lid 


 Read as positive a culture whose colonies turn bright pink within a few 
minutes. The colour soon fades. 
 
11. Potassium nitrate broth  
Potassium nitrate (KNO3) 0.2gm
Peptone                                               5.0gm 
Distilled water 100ml
 
The above ingredients were mixed and transferred into tubes and 
autoclaved.  
 
  
 
 
  
 
 
 
 
12. Phenyl alanine deaminase test  
Yeast Extract      3g 
Dl-Phenylalamine      2 g 
Disodium hydrogen phosphate       l g 
  
 
Andrade's indicator is prepared from 0.5% aqueous acid fuchsin to which sufficient 
1M sodium hydroxide has been added to turn the colour of the solution yellow. 
 
Dissolve the peptone and Andrade's indicator in 1 litre of water and add 20g of the 
sugar; sugars to be tested generally include glucose, sucrose, lactose and maltose. 
Distribute 3ml amounts in standard test tubes containing an inverted Durham tube. 
Sterilize by steaming at 100 degree C for 30 min on 3 consecutive days
Sodium Chloride 5 g 
Agar 12g 
Distilled water 1 lr 
PH 7.4 
Distributed in tubes and sterilized by autoclaving at 121° C for 1 5 minutes, 
allowed to solidify as long slopes.  
13. Sugar fermentation medium  
Peptone 15g 
Andrade's indicator 10 ml 
Sugar to be tested 20g 
Water 1 litre 
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                                      ANNEXURE-II 
 
PROFORMA 
 
Name  :   IP no / Ward: 
Age/Sex:   Address:   Occupation:    
Mechanical ventilation:   Started On-   Duration- 
 
Prior Antibiotic therapy:        Recent change in antibiotic: 
Presenting complaints: 
 
Co-Morbid Conditions: 
 
Past history:  
 
Personal history: 
 
Risk Factors:  
 
Physical examination: 
 RS:                        Temp:                                     RR: 
 CVS:                               BP:                                PULSE: 
 CNS:                                ABD:                 
 
 
  
   Laboratory evaluation: 
TC   Plasma glucose levels   
DC   Blood urea   
ESR   Sr. Creatinine   
Hb estimation   Arterial blood gas analysis    
Peripheral Smear    X-ray   
Liver function test    Others   
 
Microbiological investigation:  
Sample collected: Endotracheal Aspirate / BAL fluid /Blood 
Direct examination: 
Gram’stain:                                                                  KOH mount: 
Bacterial Culture:      
NAP:     
 
MAC:    
 
BAP/CAP: 
 
 
Biochemical reactions: 
 
Fungal culture: SDA with antibiotics. 
 
Blood culture:  
 
Isolate identified in Respiratory sample: 
 
Isolate identified in blood sample: 
 
Antibacterial susceptibility pattern: 
 
Multi- drug resistance tests- 
 
 
Antifungal susceptibility pattern: 
 
 
 
 
 
 
 
Clinical pulmonary infection score (CPIS): 
Temperature ≥38.5°C & ≤ 38.9°C Point 1  
>39°C or <36°C Point 2  
Blood leucocyte count 
(cells/mmᶾ) 
<4000 or >11000. Point 1  
+ >50% band forms Point 2  
Oxygenation(mmHg) Pa02/Fio2. <240 and no ARDS Point 2  
Chest X-ray No infiltrates Point 0  
Patchy or diffuse 
infiltrates 
Point 1  
Localised infiltrates Point 2  
Tracheal secretions 
(subjective visual scale) 
Mild/non purulent Point 1  
Purulent Point 2  
Culture & Gram stain of 
endotracheal aspirate. 
 
Moderate or heavy 
growth 
Point 1  
Same morphology on 
Gram stain 
Point 2  
CPIS score:      (CPIS score >6 → VAP) 
Diagnosis: 
Treatment: 
Outcome: 
 
                                           ANNEXURE-III 
                          PATIENT CONSENT FORM 
Title of the study: “A study on ventilator associated pneumonia  with special 
reference to multidrug resistant pathogens in a tertiary care  hospital.” 
Name :      Date  : 
Age :      IP No  : 
Sex :              Project Patient No : 
Documentation of the informed consent 
I _____________________________ have read the information in this form 
(or it has been read to me). I was free to ask any questions and they have been 
answered. I hereby give my consent to be included as a participant in “A 
study on ventilator associated pneumonia  with special reference to multidrug 
resistant pathogens in a tertiary care  hospital” and I give consent to collect 
my lower respiratory samples (Endotracheal aspirate/BAL fluid) and Blood 
sample for further investigations. 
I have read and understood this consent form and the information provided to 
me. 
I have had the consent document explained to me. 
I have been explained about the nature of the study. 
I have been explained about my rights and responsibilities by the investigator. 
I have been informed the investigator of all the treatments I am taking or have 
taken in the past ________ months including any native (alternative) 
treatment. 
I have been advised about the risks associated with my participation in this 
study.I agree to cooperate with the investigator and I will inform him/her 
immediately if I suffer unusual symptoms.I have not participated in any 
research study within the past ________ month(s). 
I am aware of the fact that I can opt out of the study at any time without 
having to give my reason and this will not affect my future treatment in this 
hospital.I am also aware that the investigator may terminate my participation 
in the study at any time, for any reason, without any consent. 
I hereby give permission to the investigator to release the information 
obtained from me as result of participation in this study to the sponsors, 
regulatory authorities, Govt. agencies, and IEC. I understand that they are 
publicly presented. 
I have understood that my identity will be kept confidential if my data are 
publicly presented.I have had my questions answered to my satisfaction.  
I have decided to be in the research study.I am aware that if I have any 
question during this study, I should contact the investigator. By signing this 
consent form I attest that the information given in this document has been 
clearly explained to me and understood by me, I will be given a copy of this 
consent document. 
 
For  participants: 
Name and signature / thumb impression of the participant (or legal 
representative if participant  in competent/For age 10-17 yrs-Name& 
signature of the parent/guardian.) 
Name ______________________________________ 
Signature_________________________ 
Date________________  
 
Name and Signature of impartial witness (required for illiterate patients): 
Name ___________________________________ 
Signature_________________________ 
Date________________ 
 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining 
consent: 
Name ___________________________________ 
Signature_________________________ 
Date________________ 
 
 
 
Master Chart: 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
           KEY TO MASTER CHART 
 
 
M Male 
F Female 
P        Present. 
N Not present. 
MND  Motor Neuron Disease. 
CVD   Cardiovascular disease. 
OPC   Organophosphorous compound. 
CKD   Chronic Kidney Disease. 
AK -Amikacin, COT-Cotrimoxazole, 
CIP -ciprofloxacin, CTX-cefotaxime, 
CAZ -ceftazidime, 
CAC -Ceftazidime & clavulanic acid, 
CX -cefoxitin, GM-Gentamicin, 
IMP -Imipenem, MER-Meropenem, 
PT -Piperacillin tazobactum. 
P -Penicillin, TET-Tetracyclin,  
 
CK -Chloremphenicol. 
 
R Resistant 
 
S Sensitive 
 
CPIS     Clinical Pulmonary Infection Score. 
 
.
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